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 1. Introduction 1 
1 Introduction 
The transport of substances across the stratum corneum, forming the diffusion 
barrier of the human skin, is a highly complex process. Therefore multiple factors 
influencing the successful delivery of the active substance into or through the skin 
have to be considered during the development of drug formulations for topical 
application. Not only are the physicochemical characteristics of the active substance, 
but also the composition of the matrix with possible permeation enhancing effects, 
relevant to the interaction of the formulation with the skin. The diffusion process and 
the pathway of the molecules are largely influenced by the interaction of the three 
components drug, matrix and stratum corneum. 
The great inter- and intrapersonal variability of skin structure causes additional 
difficulties in the comparative evaluation of formulations. This variability and the 
principle limitations of in vivo testing create the need to evaluate formulations using 
model systems providing standardized material.  
These systems are supposed to simulate the human skin regarding the diffusive 
resistance and at the same time provide the basis for a standardized evaluation. 
Some of the more simplistic in vitro models reflect only a limited number of 
influencing factors and are suitable to characterize formulations or substances but 
have a limited correlation to in vivo results regarding delivery to the skin. Models 
focusing on the comparability to in vivo results commonly use animal skin, human 
skin from surgery or artificial skin models from cell culture. Due to their tissue 
structure they mimic the diffusion process in vivo more closely. While the use of 
native human or animal skin provides a greater total diffusion barrier the cell culture 
tissues show smaller variability of barrier properties between experiments. 
2 1. Introduction  
A direct in vitro – in vivo correlation during formulation development is not necessary 
in most of the studies but correlation of an in vitro animal skin or cell culture model to 
an in vitro human skin is relevant to evaluate a therapeutic benefit. 
This assessment is often done by the determination of drug permeation parameters 
using the same formulation. This purely vertical drug diffusion evaluation is sufficient 
in order to characterize the principle barrier property of the model. For more complex 
evaluations like for example drug depot building within the skin this approach is too 
simplistic. Modified methodologies need to be applied and the characteristics of the 
chosen model have a greater influence on the result.  
The aim of this study was to characterize lateral drug diffusion in an artificial skin 
construct from cell culture in comparison to different types of human skin obtained 
from plastic surgery. Special focus was laid on the timely development of drug 
concentrations versus distance from site of application in order to investigate a depot 
building effect. If possible the observed profiles should be described by a 
mathematical function allowing a comparison of influencing parameters for the 
diffusion process in the respective skin types. The commercially available ibuprofen 
containing formulation Ibutop Creme was used directly and also modified with 
additional enhancers. Next to the lateral diffusion also drug permeation through the 
types of skin was determined using the same experimental setup. 
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2 Theoretical part 
2.1 The skin 
With a mass of up to 1/6th of the total body weight and a surface of nearly 2 m² the 
skin is the greatest human organ serving among others as interface to the 
environment. Because of the very large surface to volume coefficient and the variable 
demands depending on the localization the skin has to be considered a very diverse 
organ for example with regard to thickness, number of hairs or sensory cells.  
2.1.1 Skin functions 
2.1.1.1 Protection 
Due to its elasticity and tensile strength it provides a very efficient mechanical 
protection. The skin also protects the body against chemical agents, radiation and 
desiccation. 
2.1.1.2 Regulation 
The regulation of the evaporation of water allows temperature control aided by the 
fatty tissue as isolating layer and the micro capillary system. Furthermore the skin 
has regulating functions for the immune system. 
2.1.1.3 Perception 
Various sensory cells allow the perception of heat, cold, pain, irritation and the sense 
of touch. The speed of stimulation transport as well as adaptation to persisting stimuli 
differs in dependence on the type of receptor. 
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2.1.2 Skin structure 
The skin can anatomically be divided into three separate zones: the epidermis, 
dermis and hypodermis (more commonly also referred to as subcutis). Depending on 
the localization the thickness and also structure of each zone can differ considerably 
(fig. 2.1). While the subcutis with its fatty and connective tissue mainly functions as 
temperature isolating layer, the dermis’ supporting connective tissue accounts for the 
mechanical robustness. The epidermis provides the barrier properties of the skin due 
to the corneocytes and multiple lipid bilayers. 
 
Fig. 2.1: Cross-sectional scheme of the human skin [Pfeifer et al., 1984] 
2.1.2.1 Structure of the epidermis 
The epidermis is a typical proliferation tissue of mainly (90 %) keratinocytes. Much 
less frequent also melanocytes, lymphocytes, Langerhans-cells and Merkel-cells are 
present. While due to the nature of the skin the proportions of the other cells varies 
the melanocytes appear in a preferred 1:36 ratio [Moll, 1989] and Langerhans-cells in 
a 1:53 ratio [Bauer et al., 2001]. Additionally, nerves but no blood vessels are found. 
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Due to the resulting need of passive nourishment the structure of the interface to the 
dermis is cone shaped for surface enlargement also providing better tensile strength. 
Although different aspects for the segmentation of the epidermis based on 
mathematical considerations of cell layer organization are proposed also [Hoath and 
Leathy, 2002], most commonly the structuring is based on histological aspects. 
Inspite of earlier suggestions [Ryan, 1966] it is commonly accepted today that the 
direction of growth is directed from the epidermal-dermal borderline towards the body 
surface [Pinkus, 1970]. During their course of differentiation from keratinocytes into 
corneocytes the cells grow through microscopically distinguishable layers (fig. 2.2).  
Starting at the borderline to the dermis the stratum basale is the mitotic active single 
layer of keratinocytes dispensing cells towards the following multi layered stratum 
spinosum. Here the cells gain in size, start to transform towards a polygonal leveled 
shape and start with keratin synthesis. When the cells are fully differentiated they 
have reached the stratum granulosum bearing up to three cell layers. The cornified 
envelopes are formed and apoptosis accompanied by the proteolytic degradation of 
the nucleus takes place leading to the release of the several proteins and lipids 
contained in the cell matrix. The end of the viable epidermis is reached. 
Depending on the localization the subsequent layer of the stratum lucidum may be 
present or not. Typically this visually dense range of corneocytes is present at 
locations where also the following stratum corneum shows disproportionate thickness 
like at palms and the sole of the feet. While normally the stratum corneum consists of 
about 20 layers of desmosome connected corneocytes [Chapman and Walsh, 1990] 
providing a thickness of about 10 µm on hands and feet a size of about 500 µm is 
reported [Holbrook and Odland, 1974; Barry, 1983]. 
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The outermost layers of the stratum corneum are ablated with time and newly 
differentiated cells have to replenish the loss of cellular material by desquamation. 
The total turnover time according to literature averages around 28 days and can be 
apportioned in 2-3 weeks for the viable epidermis and another two weeks for the 
stratum corneum. This process is not only driven by physical force but is an actively 
regulated protein and enzyme linked procedure [Lundström et al., 1994; Suzuki et al., 
1994] influenced by various factors like pH, humidity, ionic strength, temperature, etc. 
[Bernard et al., 2002 and 2003; Öhman and Vahlquist, 1994]. 
 
Fig. 2.2:  Cross section of the epidermis (1 Stratum basale, 2 Stratum spinosum, 
3 Stratum granulosum, 4 Stratum lucidum, 5 Stratum corneum) 
[Wheater et al. 1987] 
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2.1.2.2 Structure of the dermis 
The most dominant cell type of the dermis is the fibroblast. Furthermore quite 
common are histiocytes like macrophages and also sporadic mastocytes and 
infrequent melanocytes. Functionally important are the several types of fibers forming 
a mechanically stable net based on mainly collagen type I. 
The dermis consists of two histologic layers, the stratum papillare and the stratum 
reticulare. The former is rather thin and provides for the connection of the dermis to 
the epidermis with frequent elastic fibrils. The latter contains the collagen fiber 
network and as well the hair follicles as the perspiratory glands originate here. 
The vascularization is subdivided into two connected layers. On the borderline to the 
subcutis the deep dermal plexus of small to mid-sized veins and arteries provides the 
basis for the sub-epidermal plexus of capillary blood vessels located in the stratum 
pallilare. This plexus guarantees for the nourishment of the viable epidermis and 
moreover regulates body temperature and blood pressure. 
2.1.2.3 Structure of the subcutis 
The subcutis consists of fatty tissue which is segregated by loose, lamelliform 
arranged connective tissue. It functions as an insulating layer, mechanical cushion 
and energy reservoir. 
2.2 Barrier function of the stratum corneum 
It is commonly acknowledged that the diffusion barrier of the skin lies within the 
stratum corneum [Scheuplein, 1976] preventing both water loss by evaporation and 
uptake of xenobiotics. The composition and the structure of the lipid phase within the 
stratum corneum are held accountable for the limitation of molecular transport. The 
8 2. Theoretical part  
concepts explaining the high barrier function range from the standard “brick and 
mortar” model [Barry, 1987] to more sophisticated models like the “mosaic model” 
[Forslind, 1994], “sandwich model” [Bowstra et al., 2000] and the “single gel phase 
model” [Norlen, 2001]. The basic principle to all these models is the organization of 
the lipid phase into lamellar phases of 6 nm and 13 nm repeat distance [Bouwstra et 
al., 2003] containing crystalline regions. This principle is also supported by 
transmission electron microscopy (TEM) pictures from morphological studies 
(fig. 2.3). 
 
Fig 2.3: TEM picture of intercorneocyte spaces in normal human stratum corneum 
(arrows: corneodesmosomes; bar = 100 nm) [Haftek, 2002] 
Studies on the formation of the intercorneocyte lamellar structure revealed that the 
mechanism is identical for mammals, birds and reptiles starting with lipid containing 
lamellar granules (fig. 2.4) in the uppermost living cells.  
These granules are then discharged into the intercellular space forming short disks 
like a flattened unilamellar liposome. During the terminal differentiation of the 
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keratinocytes these disks are transformed into continuous sheets of lipid bilayers 
through a membrane-fusion process. [Landmann, 1986] 
Fig 2.4: Lamellar granule disks from freeze fracture study (left) and profile of the 
fracture face along the X-X line (right); bar = 0.1 µm [Landmann, 1986] 
Since drug transport through the skin is not an active transport process but is 
passively driven by diffusion these stacked sheets of lipid bilayers with their 
alternating hydrophilic and hydrophobic regions function as the main barrier. 
2.2.1 Diffusion pathways 
For a local or systemic therapy with an active substance via the skin the molecules in 
a first step have to permeate through the stratum corneum before penetrating into the 
viable epidermis or deeper into the dermis where the targets for local therapy are. 
Diffusing into the blood capillary plexus of the dermis leads to a quick drainage and a 
systemic therapeutic effect. The physicochemical characteristics of the active 
substance largely determine if a local or systemic transdermal use is possible. Since 
the principle function of the stratum corneum is to hinder the infiltration of exogenic 
molecules most substances are not suitable for dermal application. Although 
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controversial discussion exists about the influence of molecular size or volume 
[Tayar et al., 1991; Guy and Potts, 1992] it is commonly accepted that smaller 
molecules of sufficient lipophilic character have the best ability to penetrate into the 
stratum corneum [Bunge and Cleek, 1995] due to its high lipid content. The more 
hydrophilic a substance is the more effective is the barrier function of the stratum 
corneum. Yet for extremely lipophilic substances with a resulting low partition into the 
viable tissue, containing greater amounts of water, an accumulation in the lower 
layers of the stratum corneum is described [Wiechers, 1989; Bock et al., 2004]. 
Hence the epidermis in total is a good barrier for both highly hydrophilic and lipophilic 
molecules while amphiphilic or slight to medium lipophilic molecules show the best 
ability for transdermal delivery. A good proven indicator for permeation capability of a 
substance is the octanol / water partition coefficient [Bunge and Cleek, 1995; Potts 
and Guy, 1995] but also other partition coefficients are referenced [Abraham et al., 
2004].  
For the passage through the stratum corneum principally three different routes can 
be differentiated and largely the molecular characteristics determine which of the 
routes predominantly is chosen. For most molecules either the intercellular or the 
transcellular route as shown in fig. 2.5 are relevant while the shunt route via the hair 
follicles and perspiratory and/or sebaceous glands is generally of minor importance 
at any rate already due to its small fraction of only about 0.1% of the human skin 
surface. 
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Fig. 2.5: Schematic view on the intercellular and transcellular route [Elias 1981] 
2.2.1.1 Transcellular route 
The diffusion across the corneocytes was the first suggested mechanism 
[Scheuplein, 1976] and is accountable mainly for the permeation of hydrophilic 
molecules. Though in some model evaluations also the primary mechanism for 
hydrophilic solutes is viewed as a diffusion process through imperfections / defects 
that occur between / within the lipid lamellar organization of the stratum corneum 
[Tezel and Mitragotri, 2003], it could be shown by fluorescence microscopy that 
diffusion through the corneocytes occurs [Yu et al., 2003]. This transcellular route is 
sometimes also referred to as “the porous pathway” or diffusion through “aqueous 
pores”. A hydrophilic molecule following this route can diffuse a large part of the 
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distance across the stratum corneum through the hydrophilic regions within the 
corneocytes but still has to cross the lipid lamellae between the corneocytes. The 
distance within the lipid phase is thus significantly reduced yet it is the rate limiting 
step leading to a noticeable lag time [Barbero and Frasch, 2006]. 
2.2.1.2 Intercellular route 
The intercellular route is widely considered to be the most relevant for the topically 
applied drugs. In recent years it was even proposed to be the only relevant 
mechanism since the drug substance transport could be modeled for a variety of 
solutes including hydrophilic ones taking solely physical properties of the substances 
like molecular volume and hydrogen bond donor and acceptor activity into account 
[Potts and Guy, 1995; Abraham et al., 1995].  
After partitioning into the lipid phase the molecules face a tortuous path along the 
intercellular channels containing structured lipid bilayers having to cross sequentially 
lipophilic and hydrophilic domains or diffusing within the sheet layers.  
2.2.1.3 Shunt route 
The permeation through hair follicles, sebaceous glands or perspiratory glands is in 
combination referred to as following the shunt route. This path is mainly a bypass for 
very large molecules or ionic solutes. Although it only plays a minor role for topically 
applied drugs from creams or ointments it could be shown that it is of significant 
importance for iontophoretic drug transport [Cullander and Guy, 1991]. Further 
modern concepts for targeted drug delivery of for instance liposomes or even solid 
particles were recently reviewed [Knorr et al., 2009]. 
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2.2.2 Possibilities for modifying the barrier function 
One of the physiological functions of the stratum corneum is to limit water 
evaporation. The determination of the transepidermal water loss (TEWL) shows 
different magnitudes of water evaporation for varying sites of the human body in 
good correlation to the determined drug penetration at the same site [Lotte et al., 
1987]. It is commonly accepted that TEWL is a reliable indicator for the quality of the 
barrier function [Shimada et al., 2008] and thus is widely used to characterize the 
stratum corneum barrier function [Savi et al., 2007; Kuntsche et al., 2008] although it 
might not be directly related to it per se [Chilcott and Emanuel, 2000].  
From the regional physiological differences for varying diffusive resistance like 
thickness of the stratum corneum layer, amount of perspiratory glands or local lipid 
composition [Lampe et al., 1983] especially the latter one gives way to an external 
modification of barrier properties. Multiple parameters influencing the permeability of 
the stratum corneum were studied. The effectiveness of most of these parameters is 
deriving from an alteration of the stratum corneum lipid organization [Lévêque, 
2002 a] while mechanical deformation of the stratum corneum of up to 16 % 
extension which results in disruption of the corneocyte cell membrane from the lipid 
bilayers does not lead to increased TEWL rates [Takahashi and Marks, 1985; 
Lévêque et al., 2002 b].  
If parameters with different mode of action as described in the following paragraphs 
are combined synergetic effects can be achieved [Hadgraft, 1999; Nicolazzo et al., 
2005]. 
14 2. Theoretical part  
2.2.2.1 Water content 
Water molecules change all the physical properties of the keratinized tissues and 
particularly increase the diffusion coefficient. The water content in the stratum 
corneum shows a gradient from the hydrous dermis to the relatively dry outer surface 
of the stratum corneum. The amount of water directly influences the organizational 
structure of the intercorneozyte lipids. Higher water levels allow a liquid crystalline 
structure and fluidization of the membranes [Alonso et al., 1995] while decreasing 
water concentrations provoke a gel state formation [Sparr and Wennerström, 2001]. 
This results in changing diffusion resistances along the water gradient. Since most 
substances rather partition into a liquid crystalline structure than into the gel state a 
significant increase in permeability can be gained from a greater hydration of the 
stratum corneum for instance by occlusion. Yet the potential effect also strongly 
depends on the characteristics of the active substance [Treffel et al., 1992; Cevc et 
al., 2008]. Therefore also the mechanism of a porous pathway for highly hydrophilic 
molecules was proposed [Tang et al., 2002]. 
2.2.2.2 Lipid extraction 
As the natural, local variability of lipid composition in the stratum corneum determines 
the barrier quality any method of extracting lipids from the lipid bilayers will alter its 
microstructure and thus also modify the barrier function [Sweeney and Downing, 
1970]. This can be an effect of the formulation’s matrix or can be caused by the 
mode of application. For instance is the effectiveness of low frequency sonophoresis 
attributed to an extraction of approximately 30 % of the intercellular lipids [Alvarez-
Román et al., 2003] besides other alterations of the lipid structure [Chesnoy et al., 
1996; Tang et al., 2001]. 
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2.2.2.3 Enhancer 
For increasing the delivery rate of active substance from a formulation additional 
excipients that interact with the stratum corneum are frequently used. These diffusion 
enhancing substances ideally possess the property that they reversibly reduce the 
barrier resistance of the horny layer, allowing the drug to reach the living tissues at a 
greater rate, without the enhancer damaging any cells. The enhancers can interact 
with stratum corneum lipids, proteins or improve partitioning of the drug, a 
co-enhancer or water into the tissue [Barry, 1991]. These effects can occur in any 
combination, depending on the physicochemical properties of the chosen enhancer. 
This will result in an enhanced permeation alongside the intercellular and / or the 
transcellular route, respectively.  
In general the three possible sites as shown in figure 2.6 for interaction with the 
stratum corneum lipids affecting mainly the intercellular route are discussed. 
 
Fig. 2.6: Proposed action sites for accelerants in the intercellular space of the horny 
layer [Barry, 1991] 
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For the enhancers depicted in figure 2.6, linear chains represent e.g. azone, bent 
chains correspond to cis-unsaturated promoters and the circles stand for small polar 
solvents such as DMSO and its analogues. 
• By interaction with the polar head groups of the lipids a disturbance of 
hydration spheres and head group interactions and thus a fluidization of this 
region can be reached. This will also increase the disorder within the lipid 
chains so that a lipophilic penetrant will then more readily permeate through 
this route. 
• By absorption of enhancers which have a solvent characteristic into the 
stratum corneum the overall chemical constitution of both, the lipid and the 
aqueous region, can be changed. This modified lipid phase / enhancer mixture 
may increase the operating partition coefficient especially for oil soluble 
molecules. 
• By intercalation between the lipid hydrophobic tails especially by structural 
changes lipophilic enhancers can increase disorder in lipid organization and 
thus also reduce polar head group interactions. 
Influence on the transcellular route is mainly reached by interactions with the polar 
head groups of the semicrystalline keratin, relaxing the binding forces and altering 
the conformations of the helices. Extensive interaction may even form pore routes 
through the tissue. 
Like the permeation abilities for active substances are estimated by their 
physicochemical properties the effect of potential enhancers is studied by structure-
activity relationship [Warner et al., 2003]. This also allows the continuous 
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development of new classes of enhancer molecules [Akimoto and Nagase, 2003; 
Lee et al., 2004]. 
2.3 Drug diffusion through skin 
Because drug passage through the skin along the routes described in 2.2.1 is not an 
active transport mechanism but a passive diffusion process the movement of the 
drug molecules is principally uninfluenced from any other molecules but depends on 
the physical parameters determining diffusion processes. Deriving from these 
parameters some general criteria a molecule should posses for successful 
permeation were formulated [Hadgraft, 2002]: 
• Be small 
• Have a low melting point 
• Possess a log (octanol-water partition coefficient) ~ 2 
• Have good solubility in both water and oils 
• Have a minimum number of pendant functional groups capable of hydrogen 
bonding 
The octanol-water partition coefficient is an indirect parameter for the expected 
solubility in the stratum corneum lipid phase which is proportional to the permeation 
rate at steady state [Tojo et al., 1987]. 
As for most molecules the diffusion through the stratum corneum will be the rate 
limiting step this is the most frequently examined step, yet for systemic delivery the 
skin has to be viewed as a three compartment tissue (stratum corneum, viable 
epidermis and dermis) with independent compartmental diffusion characteristics. 
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Furthermore the release from the formulation can be the limiting parameter if partition 
into the stratum corneum is faster than drug release. 
2.3.1 Diffusion laws 
The first Fick diffusion law describes what amount per time will pass through a 
defined area depending on the given concentration gradient. 
dx
dcDq
dt
dm ⋅⋅−=  Eq. 2.1 
 =
dt
dm  Mass flow (mass difference per time) 
  Area that the molecules pass through =q
  Diffusion coefficient [m=D 2/s] 
 =
dx
dc  Concentration gradient (concentration difference over distance) 
The only substance specific parameter in equation 2.1 is the diffusion coefficient 
which is a combined factor from numerous individual contributors as can be seen 
from equation 2.2., 
r
TkD ⋅⋅⋅
⋅= ηπ6    Eq. 2.2 
   Boltzmann constant =k
  =T  Absolute temperature 
  =η  Viscosity of surrounding medium 
  =r  Radius of the diffusing particle / molecule 
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Regarding drug substance parameters only the molecular size is accountable for the 
diffusion rate. As stated earlier (2.2.1.2) also the interaction with the lipid phase of the 
stratum corneum is of major influence. Therefore in permeation experiments the drug 
substance flux J [g/cm2·s] is determined. The parameter estimates the drug amount 
permeating through a defined skin area per time unit at perfect sink conditions and 
thus includes interaction effects of drug substance molecules and lipid phase. 
0CPJ ⋅=  Eq. 2.3 
  =P  Permeation coefficient [cm/s] 
   Donor drug concentration at start [g/cm³] =0C
The permeation coefficient includes the diffusion coefficient from Eq. 2.2, the partition 
coefficient for formulation / skin partitioning and the thickness of the skin in the 
permeation experiment. 
h
KDP ⋅=  Eq 2.4 
   Diffusion coefficient [cm²/s]) =D
  =K  Partition coefficient formulation / skin 
   Effective thickness of the skin [cm] =h
The inverse value of the permeation coefficient is also sometimes used to express 
the diffusional resistance R of a tissue (R = 1/P). 
2.3.2 Lateral drug diffusion 
While for other bilayers systems like cell membranes the investigation of lateral 
diffusion within the bilayers is frequently done in order to determine for instance the 
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mobility of proteins, within the lipid bilayers system of the stratum corneum only little 
detailed research is available [Johnson et al., 1996]. Yet it is acknowledged that the 
lateral diffusion process in the bilayers is of high importance especially for the 
intercellular route of lipophilic drug transport [Johnson et al., 1997]. Due to the 
horizontal orientation of the corneocytes (with a height to width ratio of about 1:10) 
and thus also of the surrounding bilayers (see fig 2.7) molecules with preferred 
diffusion along the bilayers will show considerable lateral movement on the way 
towards deeper skin layers. This lateral diffusion is unimportant on a macroscopic 
level for permeation experiments where the total available skin area is in contact to 
the donor and acceptor compartment but for in vivo experiments a strong influence of 
lateral diffusion on the results has been demonstrated [Weigmann et al., 1999]. It has 
been shown in in vivo experiments with rats, using non occluded finite dose 
application of radio labeled compounds with different hydrophilicity that after only 30 
minutes diffusion time considerable amounts of the drugs could be recovered 13 mm 
and even 29 mm away from the application area. The lateral diffusion was more 
pronounced for the model substance with greater lipophilic character. It was therefore 
concluded that in congruence with Johnson´s findings the lateral diffusion takes place 
mainly in the stratum corneum intercellular lipid phase. A lateral spreading of the 
formulation on the skin as accidental root cause was excluded [Simonsen et al., 
2002].  
A similar result was obtained in a human in vivo experiment studying the influence of 
the formulation using a radio labeled substance permeating for 8 h from two different 
matrices. Lateral diffusion of the drug was observed in both cases but the matrix 
delivering the greater applied dose to the contact site also showed greater lateral 
diffused amounts of drugs not only in total amount but also relative to the application 
area. So more than 10 % of the effectively applied drug amount were found in the 
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adjacent site. It was concluded that the greater permeation enhancing effect of the 
matrix also promoted lateral diffusion [Ashworth et al., 1988]. 
 
Fig. 2.7: Schematic view on surface parallel oriented corneocytes and lipid bilayers 
[Landmann, 1991] 
Also by mathematical modeling a considerable influence on bioavailability of the drug 
substance by lateral diffusion was shown for a comparative simulation of permeation 
from a coherent donor to multiple distributed donors applying the same amount of 
active substance [Reddy and Bunge, 2000]. The lateral diffusion maintains the 
concentration gradient between donor and skin contact area as driving force for drug 
diffusion for a longer period of time.  
When extrapolating in vitro results to in vivo use potential effects of the studies’ 
methodological procedures neglecting the influence of lateral drug diffusion must be 
taken into account. 
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2.4 Common models 
Several different approaches to study transdermal drug delivery are used. Depending 
on the aspect which is to be investigated a suitable level of complexity in the used 
model is necessary. Principally a simpler model can be used if a detailed parameter 
is to be assessed while more complex model are chosen to evaluate drug delivery in 
a more general perspective trying to mimic the in vivo situation as close as possible. 
2.4.1 In silico (math models) 
Mathematical models are used to simulate an observed experimental result by 
calculation based on as few parameters as possible. Often the model includes a 
hypothesis for a permeation mechanism. This approach can focus on very specific 
tasks like modeling the in vitro permeation of a special substance through a specific 
tissue [Coceani et al., 2003] or on the other hand try to predict drug delivery in 
general taking several influencing factors and pathways into account [Mitragotri, 
2003]. Also a simulation of a single permeation pathway [Johnson et al., 1997; 
Mitragotri, 2002; Barbero and Frasch, 2006] or even prediction of transdermal drug 
delivery in vivo has been published [Chandrasekaran et al., 1978; Guy and Hadgraft, 
1984; Lee et al., 1996]. Yet the overall extrapolation to in vivo conditions is viewed 
critically and requires experimental confirmation [Walters and Brain, 2000]. 
2.4.2 In vitro test models 
2.4.2.1 Lipid mixtures 
Since the intercellular lipids form the main barrier for drug permeation an artificial 
mixture of these lipids or analogous mixtures can be used for example to learn more 
about the stratum corneum lipid phase organization and behavior [Kitson et al., 1994] 
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or to study the interaction of drugs and/or excipients with the lipid phase during 
formulation development [Glombitza and Müller-Goymann, 2001]. In some set ups 
also additional corneocytes were added to the lipid mixture in order to generate a 
reconstituted stratum corneum membrane [Schendzielorz et al., 1997]. 
2.4.2.2 Siliconized membranes 
For screening testing and optimizing the permeation of drugs siliconized membranes 
can be used. Since this very simple model cannot imitate any interactions between 
the formulation and the stratum corneum lipids the obtained results are generally not 
useful to directly extrapolate to an in vivo result [Herkenne et al., 2007]. 
2.4.2.3 Animal or human skin 
A large variety of animal skins is used in publications on studying transdermal drug 
delivery. A practical reason for the use of animal skin models is the availability of 
animal or isolated animal skin compared to the availability of isolated human skin. 
Since the principle mechanism of forming the stratum corneum and its intercellular 
lipid phase is similar [Landmann, 1986] a large variety of different kinds of animals is 
used for transdermal drug diffusion testing. The selection is not only limited to 
mammalian animals like mouse, rat, rabbit or pig but also chicken and snake skin is 
used [Hirvonen et al., 1991]. Although there is principle similarity in stratum corneum 
structure significant differences in comparative experiments can occur due to 
morphological deviations (like skin thickness or amount of hairs) and different lipid 
composition. 
The most frequently used animal skins appear to be rat and pig skin. For pig skin in 
recent years an acceptable correlation of results between pig in vitro to human in 
vitro [Schmook et al., 2001] and even human in vivo [Sekkat et al., 2002; 
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Herkenne et al., 2007] experiments could be shown. But also rabbits [Shah et al., 
2006; Meshali et al., 2008] and rats [Yourick et al., 2008] are used for comparative 
studies towards human skin in vitro results. The use of rats or also frequently guinea 
pigs allows even for in vivo testing for more complex studies [Simonsen et al., 2002; 
Berner and Wagener, 1987]. 
Some more sophisticated animal skin in vitro models are developed to maintain 
tissue perfusion during the experiment so that drug elimination by simulated blood 
flow and even metabolic reactions can take place [Kietzman et al., 1993]. This helps 
to overcome the general tendency to find greater concentrations particularly of 
lipophilic drugs in the dermis in vitro compared to in vivo due to the missing 
elimination by blood perfusion [Zesch and Schaefer, 1975]. 
For the use of human skin for in vitro experiments the principle inter- and intra-
individual variability of skin in combination with the limited availability do not allow the 
widespread use for formulation development. Nonetheless numerous set ups for 
transdermal drug delivery experiments using different types of pre-treated skin have 
been published [Franz, 1975; Wagner et al., 1998]. Depending on the aim of the 
study either full thickness skin, split thickness skin, heat separated skin or isolated 
stratum corneum, to name but a few, is used. 
Direct comparability of results even from human skin in vitro to human skin in vivo 
experiments using skin from the identical individual is not always possible due to the 
influences of the experimental differences [Wagner et al., 2002]. Yet in some cases 
comparability could be shown [Bock et al., 2004] and for a comparison of drug 
delivery from several formulations [Hadgraft et al., 2003; Lombardi Borgia et al., 
2008] or of enhancing effects [Vávrová et al., 2008] using the same methodology the 
human skin in vitro testing is very appropriate.  
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2.4.2.4 Artificial skin constructs 
Artificial skin constructs (also frequently referred to as reconstructed human skin) are 
multilayered tissues built from various cell lines which are grown in cell culture. 
These immortalized cells undergo to some extent normal differentiation during the 
skin constructs cultivation period and thus form artificial tissue regions depending on 
the respective cell types. Due to the differentiation and construct geometry good 
simulation of native human skin tissue can be obtained for some aspects like 
biotransformation of active substances in the tissue [Gysler et al., 1999]. On the other 
hand the constructs’ sizes in diameter are generally smaller and the robustness 
cannot compare to natural skin. This leads to necessary changes in methodology 
conducting in vitro experiments [Dreher et al., 2002]. 
A controversial discussion is led about the suitability of artificial skin constructs for 
experiments studying drug transport processes. While some publications assign 
good correlations with human skin and only a ten-fold difference in barrier quality 
[Doucet, 1998] up to the conclusion that an extrapolation to in vivo results is possible 
[Wagner et al., 2001] it is generally acknowledged that the barrier properties of skin 
constructs is some magnitudes lower than from native stratum corneum so that for 
instance Schmook et al. [2001] conclude that porcine skin is the better in vitro model.  
A review on commercially available skin constructs also outlines that the designated 
areas of phototoxicity, corrosivity and irritancy testing are promising but the barrier 
property needs to be improved [Netzlaff et al., 2005]. In direct comparison of one 
commercial product to several types of human skin a difference in lipid composition 
was noticed and the differentiation by the diffusion barrier between two drug models 
on permeation experiments was insufficient [Netzlaff et al., 2007]. 
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One the other hand the lower barrier function allows for more sensitive testing and 
guarantees shorter experiment times, which is especially useful in large screening 
studies. 
2.5 Substances 
2.5.1 Active substance 
2.5.1.1 Ibuprofen 
O
OH
 
Molecular weight: 
Mr = 206.27 
Octanol / water partition 
coefficient: 
log Poct = 3.87 
Fig 2.8: Molecular structure of ibuprofen and relevant data [Bouchard et al., 2003] 
Ibuprofen belongs to the group of non-steroidal anti inflammatory drugs (NSAID) and 
is a racemic mixture of the (R)-(-)- and the (S)-(+)-isomer. Although the 
pharmacological activity is almost exclusively deriving from the (S)-(+)-ibuprofen the 
racemic mixture is therapeutically applied. This is reasonable since the (R)-(-)-isomer 
is transformed to about 60 % into the (S)-(+)-ibuprofen within the human body without 
observable back conversion.  
Since the anti inflammatory effect shows good correlation with the inhibition of the 
enzyme cyclooxygenase this inhibition is the accepted main mode of action.  
During local percutaneous treatment frequent (> 1/100) erythema, itching / burning 
sensation and eczema (also showing pustules and wheals) is reported. Yet from 
toxicity evaluation ibuprofen is rated to be of low irritancy in localized treatment. 
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After percutaneous application ibuprofen permeates from the respective formulation 
into deeper skin layers, joints and synovial fluid and reaches therapeutically relevant 
concentrations if suggested dosing is followed. Ibuprofen is therefore indicated for 
stand-alone or supportive topical treatment of several inflammatory and / or painful 
diseases. Daily 3 - 4 times application of 2 – 5 g of a formulation containing 5 % of 
ibuprofen (accounting to 100 – 250 mg ibuprofen / dose and up to 1000 mg / day, 
respectively) is suggested. Depending on the formulation the usual absorption rate is 
about 5 - 7.4 % [ABDATA, 2007]. The use of an occlusive patch can improve the 
therapeutic benefit. Greater penetration rates of ibuprofen can be achieved by 
iontophoresis or phonophoresis [Meshali et al., 2008]. 
Ibuprofen is a small molecule with sufficient lipophilic characteristics due to a log 
octanol-water partition coefficient (P) of around 4, and can therefore reach its site of 
action clearly beneath the transport-limiting barriers of the skin. Since the stratum 
corneum is the major barrier to permeation of NSAIDs, and it is essentially a dead 
tissue, in vitro experiments can provide relevant information about how effectively the 
NSAID will permeate in vivo. The impact of different formulation types like spray, 
mousse, cream and gel has been investigated [Herkenne et al., 2007] as well as 
differences within the same type of formulation [Hadgraft et al., 2003].  
Ibuprofen is also commonly used as model drug for numerous other types of studies 
investigating for instance permeation enhancement, [González and Sumano, 2007] 
the influence of physicochemical formulation parameters on diffusion [Zgoda et al., 
2007] or interaction effects with a second active substance on diffusion [Gu et al., 
2008]. For the evaluation of lateral diffusion in membranes like multi-lamellar 
liposomes ibuprofen was also used [Gaede and Gawrisch, 2003]. 
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2.5.2 Enhancer 
2.5.2.1 Dimethyl sulfoxide (DMSO) 
CH3
S
H3C
O
 
Molecular weight: 
Mr = 78.13 
Melting point: 
18.55° C 
Soluble in: water, ethanol, acetone, 
diethyl ether and chloroform 
Fig 2.9: Molecular structure of DMSO and relevant data 
Due to its physicochemical properties as aprotic solvent DMSO can interact with the 
skin intercellular lipids in a way that the solubilizing ability of the aqueous phase may 
increase. As an intercalating molecule it influences all three target domains for 
enhancers affecting the intercellular route and the result is that the operational 
partition coefficient now favours the development of a high drug concentration in the 
skin. But DMSO also shows influence on the intracellular route. Here interactions 
with polar groups, relaxation of binding forces and helical conformation changes are 
proposed. At higher concentrations even pore forming may appear [Barry, 1991]. The 
accumulation of DMSO in the stratum corneum leads to an increased partitioning of 
drug and / or co-enhancer like for instance propylene glycol in the case of Ibutop 
Creme from the formulation. 
For permeation enhancing use DMSO is normally used in formulations up to 
concentrations of 10 – 15 %. In therapeutic use for the treatment of acute reflex 
sympathetic dystrophy even a concentration of 50 % is used [Zuurmond et al., 1996].  
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2.5.2.2 Urea 
H2N NH2
O
 
Molecular weight: 
Mr = 60.06 
Melting point: 
132.7° C 
Soluble in: water, ethanol, 
methanol, glycerol 
Fig 2.10: Molecular structure of urea and relevant data 
The permeation enhancing mechanism of urea is assumed to derive from its 
keratolytic abilities, which is also supported by the finding of a threshold 
concentration for an enhancing effect [Shah et al., 2006]. The efficiency is relatively 
small compared to other typical enhancers. More often urea is used as a moisturizer 
in topical formulations. 
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3 Materials and methods 
3.1 Materials 
3.1.1 Commercial formulation Ibutop Creme 
As basic formulation for all experiments Ibutop Creme (Deutsche Chefaro Pharma 
GmbH, Waltrop, Germany) containing 5 % ibuprofen was used. Further excipients 
(and their functions) are:  
• propylene glycol (permeation enhancer),  
• methyl-4-hydroxybenzoate-Na (preservative),  
• middle-chain triglycerides (fatty component),  
• macrogol-glycerol fatty acid ester (surfactant),  
• glycerol fatty acid ester (surfactant),  
• macrogol stearic acid ester (surfactant),  
• xanthan gum (thickening agent) and  
• water. 
3.1.2 Ibuprofen acid 
For the calibration of the HPLC analysis racemic ibuprofen acid in pharmacopoeal 
quality from Caesar & Loretz GmbH, Hilden, Germany was used. The content 
measured by Caesar & Loretz using HPLC was 99.9 %. 
3.1.3 Dimethyl sulfoxide (DMSO) 
DMSO from Caesar & Loretz GmbH, Hilden, Germany was used. 
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3.1.4 Urea 
The urea was purchased from Caesar & Loretz GmbH, Hilden, Germany. 
3.1.5 Water 
Water of double distilled quality was used. 
3.1.6 HPLC-Mobile phase 
Acetonitrile and glacial acetic acid (both HPLC quality) were purchased from J.T. 
Baker, Deventer, Netherlands. 
3.1.7 Buffer pH 7.4 
By solving 2.38 g sodium monohydrogen phosphate (Merck, Darmstadt, Germany) 
and 0.19 g potassium dihydrogen phosphate (Merck, Darmstadt, Germany) in one 
liter double distilled water a phosphate buffer system was prepared. To adjust the 
pH-value to 7.4 (3.2.3) further potassium dihydrogen phosphate was added. 
3.1.8 Methanol as extraction medium 
For the extraction of ibuprofen from the skin samples methanol of HPLC grade from 
Fluka, Neu-Ulm, Germany was used. 
3.1.9 Reinforcement rings 
Adhesive reinforcement rings to provide a constant application area of 19.6 mm² for 
the different formulations on the several skin types were purchased from Avery 
Dennison Zweckform, Holzkirchen, Germany. 
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3.1.10 Biopsy punches 
Custom made steel punches 5, 10, 15, 20 and 24 mm in diameter, respectively, were 
used to segment skin samples. To ensure the separation into concentric rings the 
four smaller punches could be inserted in the central opening of the 24 mm punch. 
3.1.11 Dermatome 
 
Fig 3.1: Aesculap dermatome GA 630 
To obtain human skin samples of defined thickness, the dermatome GA 630 from 
Aesculap, Tuttlingen, Germany was used which was kindly provided by Dr. Ulrich 
Schäfer of the Department of Biopharmaceutics and Pharmaceutical Technology of 
the Saarland University, Saarbrücken, Germany. 
The dermatome allows adjustment of skin sample width as well as thickness by 
mechanical levers largely independent from the force or pressure during the planing 
process. 
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3.2 Methods 
3.2.1 High performance liquid chromatography (HPLC) 
The HPLC system consisted of two 515 HPLC pumps, a 712 plus autosampler and a 
486 tunable absorbance detector, all from Waters, Milford MA, USA. 
The analytical software Millenium 32 from Waters, Milford MA, USA was used for 
peak identification and integration. 
As analytical column a Hypersil ODS (particle size 5 µm) column (125 mm x 4 mm) 
from Grom, Herrenberg, Germany connected in line with a 10 mm guard column of 
the same filling was used. 
The mobile phase consisted of water, acetonitrile and glacial acetic acid 
(3.1.5 / 3.1.6) in a ratio of 54 : 46 : 2. By isocratic elution at a flow rate of 1.7 ml/min 
and 140 - 170 bar a retention time of 5.8 min for ibuprofen acid was achieved. The 
method was calibrated with an injection volume of 40 µl for the quantitation range of 
0.2 - 10.0 µg/ml with a correlation coefficient of R2=0.99983. 
3.2.2 Preparation of Ibutop Creme variations 
To obtain the enhancer containing variations of Ibutop Creme an Unguator from 
GAKO Konietzko GmbH, Bamberg, Germany was used whose homogenization 
efficacy is proven in literature [Zobel et al., 1997]. Approximately half of the Ibutop 
Creme was given into the container before the additional enhancer (3.1.3 / 3.1.4) was 
weighed in. Then the remaining amount of Ibutop creme was inserted into the 
container. The homogenization was achieved by a two minute stirring time at about 
1000 rpm at room temperature while moving the container slowly up and down.  
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3.2.3 Determination of pH-value  
Measurements of pH-values were carried out using a WTW pH 539 pH-meter from 
Wissenschaftliche Technische Werkstätten WTW, Weilheim, Germany. As pH-
electrode the single unit electrode 405-60-S7/120 from Mettler Toledo, Uhrdorf, 
Switzerland was used. Prior to the measurements the system was calibrated using 
standard buffer solutions from Merck, Darmstadt, Germany at room temperature for a 
two point calibration. 
3.2.4 Artificial skin constructs (ASC) 
The artificial skin constructs with organotypic characteristics were kindly provided by 
the colleagues of the cell culture lab belonging to the institute. 
The cultivation of the ASC was conducted according to Specht et al. [1998 a] with a 
last step modification [Wassermann and Müller-Goymann, 2000]. The human 
fibroblasts used to generate the dermis equivalent were obtained by isolation from 
newborn foreskin and were kindly supplied by Dr. Kriwet (Organogenesis, Camden, 
MA, USA). Prof. Dr. N. E. Fusenig (DKFZ, Heidelberg, Germany) supplied the 
transformed human HaCaT-cells (human adult keratinocytes, low calcium conditions, 
elevated temperature) which form the epidermis equivalent of the construct. Although 
these cells are transformed they show no tendency of malign growth and are fully 
capable to differentiate into all epithelial forms [Boukamp et al., 1988]. 
Standardized conditions according to Freshney [1990] were used to cultivate both 
cell lines, fibroblasts and keratinocytes, in Ready Mix (DMEM High Glucose, PAA, 
Linz, Austria) already containing 10 % fetal calf serum, 2 mmol L-glutamine, 100 U/ml 
penicillin G, 100 µg/ml streptomycin sulphate and 0.25 µg/ml amphotericin B. 
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The cultivation of the ASC took place in two steps, the first establishing the dermis 
equivalent and the second growing an epidermis equivalent on top of the dermis. An 
overview of the cultivation steps is given in figure 3.2. As cultivation equipment 
Transwell inserts placed into Sixwell cell culture plates (both from Costar, Fernwald, 
Germany) were used (fig. 3.2 I.) and in a later step complemented by a custom made 
metal plate bearing a six-fold boring to match the upper surface of the Sixwell 
[Wassermann and Müller-Goymann, 2000]. 
The forming of the dermis equivalent derived from the method of Bell et al. [1981] 
and started with a collagen-gel matrix, based on collagen type I gained from the 
extraction of rat tails, which was given into the Transwell inserts (fig. 3.2 II.).  
For the filling of six Transwell inserts 5.6 ml of a gelatinizing mixture consisting of 
1. 2.2 ml 10 x MEM (ICN, Eschwege, Germany), 
2. 0.2 ml L-glutamine (Gibco, München, Germany), 
3. 0.7 ml sodium hydrogen carbonate solution (71.2 mg/ml, Sigma, Deisenhofen, 
Germany)  
4. 2.5 ml fetal calf serum (Gibco, München, Germany)  
was used together with 19 ml collagen solution acidified with acetic acid (2.4 mg/ml 
sterile acetic acid 0.05 %). Prior to gelatinizing 2 ml of a fibroblast suspension, 
adjusted to about 2⋅105 cells/ml, was quickly added to the matrix of neutral pH due to 
the sodium hydrogen carbonate. After completion of the gel forming the Sixwell was 
filled up with medium and incubated for seven days leading to a slight contraction of 
the fibroblast-matrix construct proving the presence of living fibroblasts [Bell et al., 
1981]. 
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Sixwell
Transwell insert
Polycarbonate filter membrane
Fill level of medium
Collagen gel with incorporated
fibroblasts
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Contracted dermis equivalent
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IV.
 
Fig 3.2: Overview on cultivation of the ASC [modified from Tegtmeyer et al., 2001] 
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Then 2 - 2.5⋅105 keratinocytes were allocated on top of each dermis equivalent and 
again kept in submerse cultivation for another seven days changing the medium 
every 2 - 3 days (fig. 3.2 III.).  
In the following the construct was raised to the surface of the medium using the 
mentioned metal plate in order to simulate in vivo conditions by limiting the supply 
with nutrients to passive diffusion from the bottom surface (fig. 3.2 IV.).  
In this position the construct was kept for another 14 days using a different medium 
consisting of  
1. 75 % DMEM without glucose  
2. 25 % Ham’s F12 (both from Gibco, München, Germany) supplemented with  
• adenine (24.3 µg/ml),  
• insulin (5 µg/ml),  
• dexamethasone (0.4 µg/ml),  
• tri-iodine-thyronin (20 ppm, all from Sigma, Deisenhofen, Germany), 
• transferrin (5 µg/ml, ICN, Eschwege, Germany),  
• ethanolamine (6.1 µg/ml),  
• phosphorylethanolamine (14.1 µg/ml, both from Biochrom, Berlin, 
Germany),  
• selenious acid (6.8 ng/ml, Aldrich, Steinheim, Germany),  
• fetal calf serum (2 %, Gibco, München, Germany)  
• and the previously listed antibiotics. 
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3.2.5 Full thickness excised human skin (FHS) 
The native tissue derived from plastic surgery of abdominal excess skin. Only 
physiologically healthy, normal skin from caucasian, female patients was used. Skin 
from seven different patients from 20 to 39 years of age was used. 
Directly after reception the skin was cooled and the subcutaneous fatty tissue and 
connecting tissue were removed mechanically using a scalpel. The skin was used 
either directly or after shock freezing in melting nitrogen and storage at – 20° C until 
usage. The maximum storage duration for one specimen was six months which does 
not lead to any alteration of the barrier potential [Ainsworth, 1960; Bronaugh and 
Steward, 1986]. 
In order to verify the comparability of the diffusion characteristics a skin sample from 
each patient was used for qualification purpose. After applying Ibutop to the sample 
and an effective period of five hours penetration time, two biopsy samples were 
punched out and extracted. If the average content of ibuprofen per sample surface 
area was found to be between 500 and 800 µg/mm² the skin source was accepted. 
3.2.6 Planed excised human skin (PHS) 
In order to obtain skin samples of a defined thickness containing epidermis as well as 
dermis and also allowing drug permeation for some experiments the native tissue 
was prepared as described under 3.2.5 and then planed to a thickness of about 
1 mm using the dermatome described in 3.1.11. For the planing process the frozen 
skin was positioned on a plastic board and immobilized on one side by a screw 
clamp. While slowly thawing, skin strips of about three centimeters in width were 
planed from the upper surface and immediately frozen again. The frozen strips were 
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visually inspected on possible holes and suitable areas were punched out with a 
biopsy puncher of 24 mm in diameter prior to use. 
3.2.7 Lateral diffusion experiments 
While several experimental setups are common for permeation experiments a new 
methodology had to be developed for the diffusion experiments in order to study the 
lateral diffusion of substances. 
The main difference to the design of permeation experiments is that a rather small 
contact area between drug donor and skin is used while the larger skin area serves 
as diffusion compartment with contact to the buffer medium (acceptor) as visible from 
fig. 3.3. 
Modified Franz diffusion cell Diffusion setup in Transwell
Drug donor
Skin sample
Phosphate buffer
 
Fig 3.3: Comparison of Franz cell setup to lateral diffusion setup in Transwells 
The preparation of the samples followed the workflow given in fig. 3.4: 
 A circular skin sample (Ø 24 mm) was either punched out of previously excised 
(FHS) or planed (PHS) human skin or grown in the Transwells by cell culture (ASC) 
to the necessary size. In order to achieve a controllable small application area 
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adhesive reinforcement rings were stuck in the center of the circular piece of skin 
(fig. 3.4-1). 
The central hole of the reinforcement rings (Ø 5 mm) provides a constant application 
area of 19.6 mm² (3.1.9). The application of about 1.5 g ointment (3.1.1 / 3.2.2) on 
the skin (fig. 3.4-2) was done with a nasal application aid without any rubbing in of 
the cream. The systems were placed on the filter membrane of a Transwell on top of 
an isotonic phosphate buffer medium of pH 7.4 (3.1.7).  
After a variety of different exposure times (fig. 3.4-3) the skin systems were frozen at 
- 20° C (fig. 3.4-4).  
The removal of the formulation (fig. 3.4-5) and the adhesive ring as well as the 
segmentation into concentric rings (fig. 3.4-6) was carried out while the systems were 
frozen to prevent ongoing diffusion and to allow easier handling.  
¥ Ã1 2 3 4
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Fig 3.4: Sample preparation scheme for lateral diffusion experiments 
Skin rings of 0 - 5, 5 - 10, 10 - 15, 15 - 20 and 20 - 24 mm in diameter were obtained 
by the use of custom made punching tools (3.1.10) and then extracted separately in 
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methanol for at least 5 hours (3.1.8) (fig. 3.4-7). The recovery of ibuprofen from the 
several skins by this extraction was 90 ± 5 %. 
The amount of ibuprofen in the individual segments was determined by HPLC-UV 
analysis (3.2.1) against a blank extraction sample (fig. 3.4-8). For each series of 
measurements a set of at least five separate experiments was carried out. 
For the presentation of the results a line diagram deriving from the averaged content 
of ibuprofen from the parallel diffusion experiments in one experimental set for the 
five individual ring segment values is used giving the determined drug amount in 
relation to the respective ring segment surface over the medium distance from the 
center of application. To each ring segment the standard deviation to the averaged 
ibuprofen content is displayed using error bars in the respective diagrams. Fig. 3.5 
gives an exemplary overview of the connection. The numbers on the left half of the 
abscissa are inner and outer diameters of the skin sections while numbers on the 
right are median radius of the respective segment. The numbering from #1 – #5 from 
center to distal ring segment is used throughout this work to address individual rings. 
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Fig 3.5: Depiction of the relation of result diagrams to the sample preparation 
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3.2.8 Permeation experiments 
Although typically permeation experiments are carried out in modified Franz diffusion 
cells [Franz, 1975] for this study a different set-up was chosen in order to match the 
diffusion experiment conditions as closely as possible. So the permeation 
experiments were conducted directly in the Transwell inserts with circular skin 
samples of 24 mm in diameter at room temperature.  
The Transwell inserts were placed in the Sixwell boxes each on top of 2.0 ml of an 
isotonic phosphate buffer medium of pH 7.4 (3.1.7). An adhesive reinforcement ring 
was applied to the center of the skin sample providing a defined contact area of 
19.6 mm² for the test formulation. About 1.5 g of the respective formulation was 
administered maintaining a sufficient drug amount in the donor compartment. During 
the permeation time at regular intervals samples of 0.200 ml were taken from the 
buffer medium and replaced with fresh buffer solution using a 250 µl Hamilton 
syringe 1725 RN (Hamilton, Bonaduz, Switzerland). The ibuprofen content of these 
samples was then determined using the HPLC-UV method described in 3.2.1. The 
results of the analysis were entered into an excel sheet for the calculation of the 
absolute permeated amount of ibuprofen, taking the removed portions by sampling 
into account. A linear regression to the obtained averaged graph was conducted 
leading to the computational determination of flux (J) and permeation coefficient (P). 
3.2.9 Statistical data evaluation 
In order to evaluate if observed differences in results are substantial the respective 
data was assessed using a two sided t-test for two samples of different variance 
(heteroscedastic). The level of confidence for the assessment was 95% (α=0.05) and 
the resulting levels of significance (ρ) were calculated. 
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4 Results and discussion 
4.1 Consideration of the model 
The static or dynamic diffusion cells commonly used to perform bioavailability studies 
with human skin ex vivo provide an experimental set up for a precise determination of 
penetration or permeation rates only. Hence for studying the development and 
influence of lateral diffusion during drug penetration into skin (2.3.2) a modified 
experimental set up has to be chosen. In order to allow lateral diffusion an area of 
application smaller than the area in contact with the receptor fluid is necessary as 
shown in fig. 4.1. This methodology is considered to be resulting in inaccurate 
penetration rates compared to the standard penetration determination due to lateral 
diffusion [Dreher et al., 2002].  
 
Fig. 4.1: Lateral diffusion as reason for inaccurate results in conventional 
permeation experiments [Dreher et al., 2002] 
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So for the developed experimental set up it was the aim to generate the biggest 
possible ratio from receptor contact area to formulation contact area in order not to 
limit lateral diffusion. With the chosen methodology (3.2.7) using a six-well plate this 
ratio is determined by the diameter of the transwell insert of 24 mm and the diameter 
of the application area limited to 5 mm by the glued ring. This allows for a distance 
for lateral diffusion of 9.5 mm in each direction. No limitation of the lateral diffusion by 
decreasing sink conditions in lateral orientation should occur as long as in the 
outermost ring segments of the used skin do not show significant drug amounts. 
The permeation through the skin (2.2.) using this setup was also investigated in order 
to calculate the total amount of delivered drug to the skin. As stated above it is to be 
expected that permeation results will differ from conventionally determined 
permeation rates. 
Since it is the aim of this work to compare the artificial skin construct’s drug diffusion 
characteristics (2.4.2.4) to human skin characteristics (2.4.2.3) full thickness human 
skin as commonly used in several studies [Hadgraft et al., 2003; Netzlaff et al., 2007; 
Wagner et al., 2001] was employed. Additionally the planed human skin was chosen 
as model skin containing less dermis tissue since an influence of the viable epidermis 
and dermis tissue on specifically lipophilic molecules in vitro diffusion experiments, 
leading to an accumulation of the molecules in the stratum corneum, is described in 
literature [Wiechers, 1989]. 
As model drug substance ibuprofen (2.5.2) was chosen since it is commonly used as 
well for therapeutic comparison of formulations as for investigation of diffusion 
aspects. This frequent use is probably due to the sufficiently small size and lipophilic 
characteristics showing a log octanol-water partition coefficient (P) of about 4, which 
is an indirect parameter for the expected solubility in the stratum corneum lipid phase 
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[Tojo et al., 1987]. Furthermore the substance is readily available and easy to 
determine by HPLC analysis (3.2.1). Therefore the commercially available Ibutop 
Creme (3.1.1) was used as a standardized, ibuprofen containing basic formulation 
which was supplemented by DMSO (2.5.2.1) or urea (2.5.2.2) for the respective 
experiments. 
4.2 Diffusion experiments 
In this section the results for the effect of lateral diffusion in the different types of skin 
are presented deriving only from the determined drug concentrations at the end of 
the respective experiment directly within the skin. For this purpose full thickness 
human skin (FHS – 3.2.5), planed human skin (PHS – 3.2.6) and artificial skin 
constructs (ASC – 3.2.4) were selected. With each type of skin multiple diffusion 
experiments were performed as described in 3.2.7, respectively, with several 
different time periods available for drug diffusion. The data generated from these 
experiments is presented in the respective tables in the annex and is displayed in the 
several diagrams in this section. 
4.2.1 Full thickness human skin (FHS) 
The high barrier function of the native tissue causes a lag time of about 45 - 60 
minutes until first noticeable amounts of ibuprofen could be registered at the direct 
site of ointment application. Hence, the use of FHS for lateral diffusion experiments 
requires relatively long permeation times of up to 390 minutes in order to develop the 
typical concentration gradient. 
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4.2.1.1 Ibutop on FHS 
The following figure 4.2 shows the amount of drug substance determined per unit 
area [µg/mm²] of the several ring segments plotted versus the respective distance 
from the center of application [mm] following the principle diagram structure 
introduced in 3.2.7, figure 3.5. Each individual line represents a specific diffusion time 
period ranging from 90 – 390 minutes. The number of parallel experiments (n) is 
given in brackets. In order to establish a better understanding the zone reflecting the 
area with direct contact to the drug formulation is depicted as a grey layer. 
 
Fig. 4.2: Lateral diffusion profiles for Ibutop on full thickness human skin 
Analyzing the concentration of ibuprofen in the several ring segments a characteristic 
concentration gradient development over time can be observed. These concentration 
gradients all show significant amounts of the model drug substance in the distal ring 
segments proving that lateral diffusion takes place. 
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In the beginning the concentration of ibuprofen in the central area with direct contact 
to the drug containing formulation rises rapidly with time. After reaching a maximum 
at about 270 minutes a gradual incline of concentration follows.  
The region directly alongside of the application area (3.75 mm from center) also 
shows a quick increase with time but the concentration of ibuprofen is always 
distinctly lower than in the central section (#1). In contrast to the central segment no 
clear maximum in concentration development is noticeable but a tendency for a 
continuous increase. 
For ring segment #3 (data points at 6.25 mm from center of application) no significant 
concentration development with timely resolution can be deducted from the 
experimental results. Yet the 390 minutes result indicates a tendency for a 
continuous concentration increase. This is supported by the results for the two 
outmost ring segments containing detectable amounts of ibuprofen. 
 
Fig. 4.3: Accumulation and redistribution phases during diffusion experiments 
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Due to the seen maximum in the drug concentration development within the skin 
directly in contact with the formulation the total diffusion time period can be separated 
into two stages. The first stage is characterized predominantly by drug penetration 
into the skin segment with direct formulation contact. In the second stage this 
diffusion process is less dominant but the effects of lateral diffusion attract notice. So 
in the first stage the initially penetrating drug amount accumulates in the central area 
of the skin and is then redistributed in the second stage leading to the decrease in 
central drug concentration. A schematic diagram emphasizing these two phases in 
the concentration development is shown in figure 4.3 where the accumulation phase 
is displayed by the blue curves and the redistribution phase is represented by the 
reddish colored curves. 
In the following paragraphs of this chapter the results for each set of diffusion 
experiments are displayed separately in connection to the two phases accumulation 
and redistribution, respectively (see for example 4.2.1.1.1 and 4.2.1.1.2 for this set of 
experiments). This also allows for a better differentiation between diffusion durations 
due to a smaller number of graphs in one diagram. 
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4.2.1.1.1 Accumulation phase from Ibutop on FHS 
 
Fig. 4.4: Accumulation phase from Ibutop on FHS 
In fig. 4.4 the profiles for the accumulation phase obtained from diffusion experiments 
with Ibutop on FHS are plotted as drug concentration per area unit [µg/mm²] over 
distance from the center [mm]. The shape of the profiles regarding the slope for the 
first three ring segments (#1 - #3) moves from a linear towards an exponential 
shaped curve.  
After 90 minutes a quantifiable amount of ibuprofen is seen at the site of application 
as well as in ring #2. The drug concentration in the center increases constantly with 
time so that after about the double time the double drug amount is found. Yet during 
the next 90 minutes the increase slows down and a maximum concentration is 
reached. The relative drug concentration in the skin segment #2 compared to the 
center segment (#1) develops more slowly. While after 90 minutes about 60 % of the 
central concentration was recorded, after 195 minutes some 45 % of the central 
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concentration is found and after 270 minutes only about 30 % of the central 
concentration at the respective time is determined. The three outer segments (#3 -
 #5) only develop minimal drug concentrations within 270 minutes. 
4.2.1.1.2 Redistribution phase from Ibutop on FHS 
Figure 4.5 shows that 60 minutes later (330 min total diffusion time) the drug 
concentration within ring segment #1 decreases significantly (ρ < 0.05) while section 
#2 remains at the previously observed level. This tendency is confirmed by the 
finding of a decisively lower drug concentration in the center section (#1) after 390 
minutes (ρ < 0.01). While the concentration in ring segment #2 at 390 minutes shows 
only a minimal tendency of increasing drug level a relevant relative rise in drug 
concentration is seen in comparison to the accumulation phase for segment #3 
(ρ < 0.001).  
 
Fig. 4.5: Redistribution phase from Ibutop on FHS 
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The shape of the profiles develops from the exponential shape from the accumulation 
phase back towards a linear gradient at 330 minutes. This trend in development 
within the first three segments (#1 - #3) then leads to the forming of a shoulder at 390 
minutes. 
4.2.1.2 Ibutop + 5 % urea on FHS 
4.2.1.2.1 Accumulation 
 
Fig. 4.6: Accumulation phase from Ibutop + 5 % urea on FHS 
Compared to the application of Ibutop, using urea as additional permeation enhancer 
a slightly higher drug content at the central section (#1) already after 90 minutes is 
observed as can be seen in figure 4.6. At this point of time all other segments show 
results similar to the 90 minute profile of only Ibutop as donor. At later time points 
during the accumulation phase this trend can be seen to a greater extent leading to 
higher ibuprofen contents for segments #1 - #3. The drug amounts in segments #1 
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and #2 at about 180 min are at a level of about 10 % above the values from only 
Ibutop. Even more intense is the relative increase for segments #3 and #4 but due to 
rather high standard deviation this difference cannot be evaluated with sufficient 
significance (ρ > 0.05). 
The profile shape for segments #1 - #3 again develops from linear slope to 
exponential slope but less distinctly compared to Ibutop only. 
4.2.1.2.2 Redistribution 
 
Fig. 4.7: Redistribution phase from Ibutop + 5 % urea on FHS 
In order to determine the transition from accumulation to redistribution phase more 
precisely the additional time point of 300 minutes diffusion time was taken up for the 
FHS experiments. Compared to the 270 minutes profile the results show only a 
marginal decrease for section #1 while all other sections experience a slight increase 
in drug concentration. Hence it can be assumed that from this point of time on the 
redistribution process is the dominating mechanism. 
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Evaluating the 330 minutes and 390 minutes profiles against the results obtained 
with only Ibutop, especially the segments #3 - #5 appear to gain larger amounts of 
ibuprofen but also the segments #1 and #2 show higher drug contents. 
4.2.1.3 Ibutop + 5 % DMSO on FHS 
4.2.1.3.1 Accumulation 
 
Fig. 4.8: Accumulation phase from Ibutop + 5 % DMSO on FHS 
The use of DMSO, instead of urea as additional permeation enhancer, leads to an 
accumulation phase as can be seen in figure 4.8 with profiles which are quite similar 
for segments #1 and #2 to the profiles obtained using urea. Yet for sections #3 – #5 
even higher drug concentrations are recorded. The drug content of sections #2 – #5 
of the 270 minutes profile matches closely the results of the 390 minutes profile 
obtained with Ibutop only. Section #1 however shows the high content which is 
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typical for the end of the accumulation phase and no difference to the content 
resulting from the use of urea can be seen. 
4.2.1.3.2 Redistribution 
 
Fig. 4.9: Redistribution phase from Ibutop + 5 % DMSO on FHS 
In general the redistribution phase using Ibutop + DMSO is quite similar to the one 
using Ibutop + urea as well as to Ibutop only regarding the profiles’ slope change, 
respectively. Again the 300 minutes profile shows a slight decrease for section #1 
while sections #2 – #5 continuously increase. The decrease of ibuprofen 
concentration in section #1 proceeds distinctly slower than during the redistribution 
phases of Ibutop or Ibutop + urea. On the other hand a still greater increase for 
sections #2 – #5 is seen. 
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4.2.1.4 Comparison of formulation effect on FHS 
The following figures 4.10 – 4.13 show selected data obtained from the above 
experiments presented in 4.2.1.1 – 4.2.1.3 re-grouped in such a way that the 
influence of the formulation, and thus the contained enhancer (2.2.2.3 / 2.5.2.1 / 
2.5.2.2), can be directly compared. For this overview the respective start and end 
data sets for the accumulation phase (90 and 270 minutes) and redistribution phase 
(330 and 390 minutes) were chosen. 
After 90 minutes (fig. 4.10) of drug diffusion both enhancer containing formulations 
show a tendency to greater drug amounts in the central skin segment while all 
adjacent skin segments do not show any considerable differences. 
At the end of the accumulation phase at about 270 minutes (fig. 4.11) with all 
formulations similar maximal drug contents were determined in the central segment. 
The ibuprofen concentration in ring segment #2 is also on the same level. Yet 
significant differences are seen for ring segments #3 and #4. Both additional 
enhancer containing formulations provoke a seven fold concentration (ρ < 0.001) in 
segment #3 and a four fold concentration (ρ < 0.01) in segment #4, respectively. No 
difference in drug amount is seen in ring #5.  
Although no significant difference between the formulations was seen for the drug 
content in segment #1 during the accumulation phase, after 330 minutes the DMSO 
containing formulation shows an about 30 % greater drug level in this segment 
compared to Ibutop only (ρ < 0.05) as can be seen in figure 4.12. No relevant 
difference is seen for the urea enriched formulation (ρ > 0.05). For the ring segment 
#2 a 1.5 fold and for ring segments #3 and #4 a 2.5 – 3 fold greater ibuprofen 
content, respectively, was determined always with a slight advance for the DMSO 
formulation. 
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Fig. 4.10: Comparison of the permeation enhancing effect of urea and DMSO for 
ibuprofen from Ibutop on FHS after 90 minutes 
 
Fig. 4.11: Comparison of the permeation enhancing effect of urea and DMSO for 
ibuprofen from Ibutop on FHS after 270 minutes 
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Fig. 4.12: Comparison of the permeation enhancing effect of urea and DMSO for 
ibuprofen from Ibutop on FHS after 330 minutes 
 
Fig. 4.13: Comparison of the permeation enhancing effect of urea and DMSO for 
ibuprofen from Ibutop on FHS after 390 minutes 
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This decline in relative drug concentration (between Ibutop and Ibutop + enhancer) 
for segments #3 and #4, from 7 fold and 4 fold after 270 minutes to 2.5 – 3 fold after 
330 minutes, is not caused by lower absolute drug contents in these ring segments at 
330 minutes for the enhancer containing formulations but mainly due to the faster 
relative increase (from 0.007 µg/mm² to 0.031 µg/mm²) for the Ibutop formulation 
without enhancers. 
Figure 4.13 shows the comparison after 390 minutes where for both ring segments 
#1 and #2 a relevant drug level increase can be observed for the enhancer 
containing formulations. With additional urea about 35 % greater concentrations were 
achieved (ρ < 0.01 for ring #1 and #2) while DMSO even allows 55 % higher drug 
amounts in these two segments (ρ < 0.001). For the distal three sections (#3 - #5) an 
about two fold increased ibuprofen content is noted, again with slight but not 
significant advantage for the DMSO formulation. 
In general comparison over the total diffusion times both enhancer containing 
formulations deploy their enhancing effect quite similar. A slight advantage for the 
DMSO containing formulation is seen the more pronounced the longer the diffusion 
time is. Most interestingly the first significant enhancer activity is the increase in the 
ring segments #3 and #4 and thus an enhancement of mainly the lateral diffusion at 
the end of the accumulation phase after about 270 minutes. It can be therefore 
concluded that the lateral diffusion in the stratum corneum lipid phase (2.2.1) is the 
main transport mechanism for a lipophilic molecule like ibuprofen and hence the 
permeation enhancing effect shows a larger impact on lateral drug movement 
compared to the vertical direction.  
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4.2.2 Planed human skin (PHS) 
The planed human skin (3.2.6) lacks larger parts of the dermis and therefore has less 
viable tissue forming a diffusion barrier for lipophilic molecules (2.2.1). The same 
methodological set up as for full thickness human skin was used for the diffusion 
experiments. Also the identical type of diagram showing the amount of drug 
substance determined per unit area [µg/mm²] of the several ring segments plotted 
versus the respective distance from the center of application [mm] is used. The skin 
for the PHS experiments derived from only one source with quality differences only 
due to inter-individual variances of the skin at different body regions. Due to therefore 
limited availability of PHS fewer time points were investigated and special focus was 
laid on the transition from accumulation to redistribution phase with this type of skin. 
Also the urea containing formulation was omitted since DMSO showed to be the 
more efficient enhancer in the previous experiments with FHS. 
4.2.2.1 Ibutop on PHS 
Since with FHS at 90 minutes diffusion time no relevant differences between 
formulations with and without enhancer were seen the first diffusion time to be 
examined was 180 minutes. The next time points were chosen with an interval of 60 
minutes from one another. Already after 300 minutes a decrease in central drug 
concentration was seen and therefore the curves from that time on attributed to the 
redistribution phase. 
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4.2.2.1.1 Accumulation 
 
Fig. 4.14: Accumulation phase from Ibutop on PHS 
Both of the curves in figure 4.14 from 180 and 240 minutes diffusion time, 
respectively, exhibit an exponential shape. The relatively small increase in drug 
concentration in the segment #1 from 180 to 240 minutes compared to the drug 
amount increase for the first three hours already indicates that after about 240 
minutes the drug accumulation is reduced and the transition towards the 
redistribution phase starts. 
4.2.2.1.2 Redistribution 
The 300 minutes curve in figure 4.15 shows the significantly reduced (ρ < 0.001) drug 
amount in the central skin segment (#1) compared to the 240 minutes result and at 
the same time the curve shows a linear profile over the first three segments (#1 - #3) 
as was also seen with FHS. Consequently already 30 minutes later the forming of the 
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shoulder by noticeable increase (ρ < 0.05) of drug concentration in ring segment #3 
starts. 
 
Fig. 4.15: Redistribution phase from Ibutop on PHS 
 
Fig. 4.16: Accumulation phase from Ibutop + 5 % DMSO on PHS 
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4.2.2.2 Ibutop + 5 % DMSO on PHS 
4.2.2.2.1 Accumulation 
Although the curves of figure 4.16 show close similarity to the ones obtained from 
Ibutop only in figure 4.14, a slightly bigger increase in ibuprofen concentration of 
segment #3 can be noticed. Both curves also present an exponential slope. 
4.2.2.2.2 Redistribution 
 
Fig. 4.17: Redistribution phase from Ibutop + 5 % DMSO on PHS 
The 300 minutes curve in figure 4.17 shows reduced drug amounts in the central 
segment (#1) indicating that the redistribution phase is reached. Furthermore the 
curve has a linear profile for the first three segments (#1 - #3). The 330 minutes 
curve clearly exhibits increased drug levels in segments two (ρ > 0.05), three 
(ρ < 0.01) and four (ρ < 0.05) compared to the 300 minutes curve while segment #1 
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continues with the declining in ibuprofen concentration. This, again, produces the 
typical shoulder due to lateral diffusion. 
4.2.2.3 Comparison of formulation effect on PHS 
The previously shown data from 4.2.2.1 and 4.2.2.2 is presented in the following 
diagrams 4.18 to 4.21 in a re-grouped organization so that a direct comparison of the 
formulation related effects can be viewed. 
During the accumulation phase (fig. 4.18 and 4.19) close similarity between the 
concentration profiles from both formulations can be seen with a tendency to greater 
permeated drug amounts for the DMSO containing formulation. 
Also for the redistribution phase (fig. 4.20 and 4.21) still a resemblance of drug levels 
is seen but with a stronger tendency towards greater penetrated drug amounts for 
the DMSO containing formulation with longer diffusion duration.  
One difference in profile development is noted between the 300 minutes to 330 
minutes diagrams for ring segment #2. While with the Ibutop formulation a minimal 
decrease in the segment is observed, the DMSO added formulation generated a 
10 % increase in drug content for this segment. 
While for the first three ring segments (#1 - #3) an elevated ibuprofen concentration 
of up to 25 % is seen, increases of up to 60 % are determined for the DMSO 
formulation in ring segments #4 (ρ < 0.05 at 330 min) and #5 (ρ < 0.05 at 300 min). 
So generally the relative differences between the formulations are more intensely 
seen in the distal ring segments indicating that the enhancing effect of DMSO is 
primarily related to the improvement of lateral diffusion. 
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Fig. 4.18: Comparison of the permeation enhancing effect of DMSO for ibuprofen 
from Ibutop on PHS after 180 minutes 
 
Fig. 4.19: Comparison of the permeation enhancing effect of DMSO for ibuprofen 
from Ibutop on PHS after 240 minutes 
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Fig. 4.20: Comparison of the permeation enhancing effect of DMSO for ibuprofen 
from Ibutop on PHS after 300 minutes 
 
Fig. 4.21: Comparison of the permeation enhancing effect of DMSO for ibuprofen 
from Ibutop on PHS after 330 minutes 
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4.2.3 Artificial skin construct (ASC) 
The artificial skin construct (3.2.4) consists of an artificial epidermis from 
keratinocytes and a dermis out of fibroblasts in a collagen gel matrix. So the principal 
tissue structure (2.1.2) is identical to native skin but a distinctly lower mechanical 
robustness is given. The thickness of the skin constructs is comparable to that of the 
planed skin. 
While the native skin samples always had a diameter of 24 mm due to the biopsy 
punch the ASC show a smaller diameter. This is due to the constriction of the 
fibroblast/collagen gel dermis equivalent during the cultivation in the 24 mm 
transwells. Therefore the factual diameter of each construct was measured and the 
determined drug concentration from ring segment #5 was calculated with regard to 
the available respective ring segment surface. The experiments with ASC rely on 
separate batches of constructs for each individual diffusion time point. Due to a 
standardized cultivation of the ASC a sufficient equivalence of the single batches is 
granted. 
Again the methodology described in 3.2.7 was used to generate the data presented 
in the following diagrams showing the amount of drug substance determined per unit 
area [µg/mm²] of the several ring segments plotted versus the respective distance 
from the center of application [mm]. 
4.2.3.1 Ibutop on ASC 
Since it is known from previous permeation experiments using the ASC with various 
drug substances [Specht et al., 1998 a; Winkler, Müller-Goymann 2002] that the 
diffusion barrier properties of the construct is considerably lower than from human 
stratum corneum quicker diffusion of ibuprofen was to be expected (2.3.1 / 2.4.2.4). 
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Therefore shorter intervals for the several diffusion experiments were chosen. The 
experimental results indicate that the transition from accumulation phase to 
redistribution phase takes place between 60 - 120 minutes of diffusion time using 
ASC. 
4.2.3.1.1 Accumulation 
 
Fig. 4.22: Accumulation phase from Ibutop on ASC 
As can be seen in figure 4.22 the drug concentration profile development in ASC also 
proves lateral drug diffusion starting with a linear concentration decrease for the first 
three segments (#1 - #3) and then developing towards an exponential graph 
structure towards the end of the accumulation phase at about 60 minutes. While 
already significant amounts of drug are determined in the ring segments #3 and #4 
after 10 minutes only little change in concentration is observed over time for these 
segments. 
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4.2.3.1.2 Redistribution 
 
Fig. 4.23: Redistribution phase from Ibutop on ASC 
Also for ASC the profile development is characterized by a drug decrease in section 
#1 while section #2 remains rather unchanged and sections #3 – #5 show a relevant 
increase of ibuprofen content (#3: ρ > 0.05; #4: ρ < 0.05; #5: ρ < 0.01). The shape of 
the profile also shows a tendency to develop backwards from exponential to linear 
drug concentration decrease over the first three segments (#1 - #3). Yet the 
formation of a shoulder is not clearly seen due to the little change in drug 
concentration of segment #2 although the trend of increasing concentrations at 250 
minutes after previous decrease suggests that a shoulder might appear at later 
times.  
The untypical dent in the 210 minutes curve for ring segments #3 to #5 may be 
attributed to a lack in precision during the dissection of the skins falsely transferring 
some of the higher drug concentration from ring #3 to ring #4. 
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4.2.3.2 Ibutop + 5 % DMSO on ASC 
4.2.3.2.1 Accumulation 
 
Fig. 4.24: Accumulation phase from Ibutop + 5 % DMSO on ASC 
Again effects from lateral diffusion are noticeable already from the short term 
diffusion results. With DMSO also for ring segment #2 an increase in drug 
concentration over time is observable in figure 4.24. No significant change in drug 
levels is seen for segments #3 – #5. 
4.2.3.2.2 Redistribution 
The diffusion profile shape as depicted in figure 4.25 also develops from exponential 
to a more linear character for the first three ring segments (#1 - #3). Since the drug 
level in segment #2 remains unchanged no shoulder formation can be seen.  
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Fig. 4.25: Redistribution phase from Ibutop + 5 % DMSO on ASC 
Comparing the 120 minutes to the 240 minutes curve significantly different ibuprofen 
concentrations are found for all segments but #2. So a significant reduction in drug 
content for the central segment (#1) was determined (ρ < 0.01) while segments #3 –
 #5 show a significant increase with more than doubled amounts for segments #4 
and #5 (#3: ρ < 0.001; #4: ρ < 0.001; #5: ρ < 0.01). 
4.2.3.3 Comparison of formulation effect on ASC 
In order to compare the data shown in 4.2.3.1 and 4.2.3.2 evaluating the effect of 
DMSO as enhancer it has to be noticed that for the data during the redistribution 
phase not absolutely identical diffusion times were used. Since the respective 
differences are small compared to the absolute duration, comparability of the results 
is still assumed and the average of the time points is used for denomination. 
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Fig. 4.26: Comparison of the permeation enhancing effect of DMSO for ibuprofen 
from Ibutop on ASC after 10 minutes 
 
Fig. 4.27: Comparison of the permeation enhancing effect of DMSO for ibuprofen 
from Ibutop on ASC after 60 minutes 
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Fig. 4.28: Comparison of the permeation enhancing effect of DMSO for ibuprofen 
from Ibutop on ASC after 128 minutes 
 
Fig. 4.29: Comparison of the permeation enhancing effect of DMSO for ibuprofen 
from Ibutop on ASC after 245 minutes 
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For the accumulation phase the principle tendency to increased drug amounts using 
the DMSO containing formulation can be seen in figures 4.26 and 4.27. For most ring 
segments the relative increase in ibuprofen concentration is at least 10 % with a 
trend to greater relative increase for distal ring segments. 
On the other hand relevant to significant enhancement effects during the 
redistribution phase (fig 4.28 and 4.29) can only be seen for ring segments #1 
(ρ > 0.05 at 128 min; ρ < 0.05 at 245 min) and #2 (ρ < 0.01 at 128 min; ρ < 0.001 at 
245 min). In the segments #3 – #5 only for the long diffusion duration a slight effect 
from the enhancing effect of DMSO can be seen (fig. 4.29). 
4.2.4 Comparison of diffusion results for the different types of skin 
Since it is the aim of this work to evaluate the comparability of the artificial skin 
construct to human skin in vitro, the generated results are re-grouped into figures 
4.30 – 4.33 to allow for a comparative assessment of the different types of skin 
regarding the diffusion profiles at the end of the accumulation phase and at the late 
redistribution phase from Ibutop and Ibutop + 5 % DMSO. 
Over all the development of the ibuprofen concentration profiles follows the same 
pattern for all types of skin characterized by the two phases of accumulation and 
redistribution as described earlier (4.2.1.1). So in all types of skin the concentration 
gradient develops from a linear towards an exponential slope over the first three ring 
segments (#1 - #3) at the end of the accumulation phase (fig 4.30 and 4.32). After 
this phase the central concentration decreases in all skin types and by that 
transforms the slope from exponential to linear again. Then a difference from profile 
development from ASC to the human skins as shown in figures 4.31 and 4.33 can be 
observed: while in the native tissue a drug concentration shoulder is formed over ring 
segment #2 this phenomenon is not observed for the ASC profiles. This could be 
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related to either a different proceeding of the diffusion process or simply to an 
insufficient diffusion time in order to show the shoulder. 
Comparing the time span until the estimated end of the accumulation phase for the 
types of skin, not surprisingly a clearly shorter period is found for the ASC which is 
related to the lower diffusion barrier of the tissue. Based on the ratio from time until 
end of accumulation phase to time until shoulder forming for FHS and PHS, it can be 
assumed that the time span for the ASC was sufficient as a shoulder forming would 
be expected already after about 90 minutes if the identical diffusion mechanism 
occurs (see table 4.1). The slight deviations from FHS to PHS concerning the 
absolute times may be attributed to individual differences of the skin donors.  
 
Fig. 4.30: Comparison of the profiles at the end of the accumulation phase from 
Ibutop 
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Fig. 4.31: Comparison of the profiles late in the redistribution phase from Ibutop 
 
Fig. 4.32: Comparison of the profiles at the end of the accumulation phase from 
Ibutop + 5 % DMSO 
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Fig. 4.33: Comparison of the profiles late in the redistribution phase from Ibutop + 
5 % DMSO 
A potent difference in the diffusion mechanism process could be a reuptake of 
ibuprofen from the acceptor medium during the experimental diffusion time. This 
should lead especially to increased drug contents in the distal rings due to lower 
intrinsic ibuprofen concentrations compared to the central segments. Thus a uniform 
increase in distal drug concentrations could cover up a slight shoulder forming. Due 
to the lower permeation barrier in ASC, larger drug amounts per time should 
permeate into the acceptor medium compared to PHS and it is therefore more likely 
to see influences of reuptake from the buffer using ASC. 
A clear difference between the full thickness human skin to PHS and ASC is the 
significantly greater drug amount in the ring segments #1 and #2 in FHS. A logical 
explanation for this observation is that with FHS no permeation through the skin into 
the acceptor medium takes place (see also 4.4.1.1) but all penetrated ibuprofen 
remains in the skin as the viable epidermis and dermis are known to be a diffusion 
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barrier for lipophilic substances and additionally the thickness of this type of skin is 
bigger thus prolonging the pathway to the acceptor medium. With PHS and ASC, on 
the other hand, permeation occurs and the ibuprofen leaving the tissue into the 
acceptor medium cannot be detected by tissue extraction. 
Table 4.1: Ratios of phase durations 
 Duration of accumulation phase Time until shoulder is formed Ratio 
FHS 270 min 390 min 1 : 1,4 
PHS 240 min 330 min 1 : 1,4 
ASC 60 min > 245 min 1 : >4,1
 
This also has to be taken into account for the evaluation of the enhancer effects. 
Comparing the FHS results for drug concentration in the central segment (#1) a 
remarkably smaller decrease in concentration from end of accumulation phase to 
redistribution phase is observed using the DMSO containing formulation. The PHS 
and ASC results do not show a relevant difference for this aspect as can be seen 
from table 4.2.  
Table 4.2: Decrease diminution from end of accumulation (EA) to late 
redistribution (LR) phase for segment #1 
Ibutop Ibutop + 5 % DMSO  
EA 
[µg/mm²] 
LR 
[µg/mm²] 
Decrease 
[µg/mm²] 
EA 
[µg/mm²]
LR 
[µg/mm²]
Decrease 
[µg/mm²] 
Decrease 
diminution
FHS 0.771 0.355 0.416 0.803 0.556 0.247 41 % 
PHS 0.443 0.231 0.212 0.459 0.263 0.196 8 % 
ASC 0.436 0.263 0.173 0.466 0.311 0.155 10 % 
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This indicates only a slightly improved solubility of ibuprofen in the skins leading to 
the minimal increase within ASC and PHS while the largely improved penetration 
without subsequent permeation causes the noticeable difference in FHS. 
For all three types of skin, independently from the formulation, at least some 65 % of 
the contained ibuprofen resides outside of the central ring (#1) at the end of the 
accumulation phase. About 80 – 85 % of the total drug amount in the respective skin 
was found in the lateral ring segments #2 – #5 at the end of the experiments in late 
distribution phase. Yet the distribution of drug within the four lateral rings was more 
oriented towards the center with FHS than with PHS / ASC due to the larger total 
amount deriving from penetration. This uniformity in percentage development firstly 
emphasizes the relevance of the lateral diffusion and secondly underlines that the 
ASC provides results well comparable to human skin. 
4.3 Diffusion model 
Since great similarity in the concentration development for all skin types and 
formulations regarding the principle mechanism was observed from the results 
presented in this section (4.2) an attempt to match the spatiotemporal development 
on the basis of a mathematical function (2.4.1) was made. 
The principal observation of two phases (accumulation and redistribution) with a 
strongly time dependent specificity has to be reflected in the three dimensional 
function by two separate terms, each one describing one of the respective phases in 
connection to the diffusion time. Because the lateral diffusion effect is also influenced 
by co-diffusion of enhancers it is a distance dependent function which has to be 
reflected in the respective term.  
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Expected influencing parameters for the total function are the maximal content of 
ibuprofen per area in the middle of ring segment #1 (Cmax) and the point of time when 
this takes place (tmax) as discriminator for the shift between the phases. Furthermore 
some parameters compensating the individual skin and formulation characteristics 
need to be included. 
The function that evolved from the above considerations empirically is given in 
equation 4.1 calculating the content C(t,d) [µg/mm²] against time t [min] and distance 
from center of application d [mm]. 
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,  Eq. 4.1 
   Time [min] that the formulation is applied on the skin =t
   Distance [mm] from the center of formulation application =d
  Content maximum [µg/mm²] at application site during accumulation phase =maxC
  Diffusion time [min] until concentration maximum is observed =maxt
  Skin and formulation dependent parameters =srba ,,,
For the determination of parameter settings in order to fit to a set of experimental 
results the observed values for Cmax and tmax can be used only as initial 
approximations. 
Regarding Cmax it has to be taken into account that the mathematical function will 
require a greater value than it is observed for the central ring (#1). This is due to the 
fact that practically the average content for the total ring segment is determined and 
therefore reflects the content at 1.25 mm from the center while the function requires 
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the maximum directly in the center assuming a punctual application of the 
formulation. 
With respect to the experimentally determined tmax it is obvious that choosing the 
ideal experimental diffusion time a priori is highly unlikely. The true value might 
therefore be as well earlier as later and can be estimated fitting the function to the 
obtained experimental data. 
Besides the functional variables t [min] and d [mm] the four constants a,b,r and s had 
to be integrated into the function in order to allow for the best possible fit to the 
experimental results.  
The constant a in the term for the accumulation phase determines the slope of the 
principally bell shaped content development in the central ring segment (#1) and 
therefore modulates how quickly the content increases and decreases over time. 
The parameter r in the redistribution term together with b as basis for the exponential 
expression controls the shoulder forming process at later diffusion times. The 
principle slope of the content profiles (displayed as drug amount [µg/mm²] over 
distance [mm]) is largely influenced by the constant s towards either more 
exponential or linear shape over the first three ring segments (#1 - #3). 
4.3.1 Parametrical fit to experimental results 
The parameters were adapted as described above for each set of experiments 
carried out with Ibutop and Ibutop + DMSO in order to find a best match over all 
several diffusion time points belonging to one experimental set. 
The following two diagrams show the experimental results for Ibutop on ASC in 
comparison to the model prediction (in dotted lines) separated into accumulation 
(fig. 4.34) and redistribution phases (fig. 4.35). 
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When evaluating the quality of the fit to the data set it has to be taken into account 
that for each time point a different batch of ASC was used and therefore certain 
variability is to be expected. Bearing this in mind the fitted curves in figure 4.34 are 
sufficiently matching the experimental data. Although it appears that for early time 
points the model overestimates the content in the central ring (#1) by trend all curves 
lie within the error bar range of the respective experimental curve. 
 
Fig. 4.34: Comparison of experimental results as solid lines / symbols for the 
accumulation phase from Ibutop on ASC to the respective time points in 
the mathematical fit, displayed in dotted lines 
The 135 minutes diagram in figure 4.35 very closely matches the experimental 
correspondent except for a slightly bigger discrepancy in ring segment #2. A bigger 
deviation is seen after 210 minutes for the content in ring #1 which is calculated to 
contain less drug substance than was found in the experiment. On the other hand the 
unusual ripple seen from the ring #4 and #5 data most likely has to be attributed to 
an experimental handling error transferring drug amounts errantly to ring #4. 
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Fig. 4.35: Comparison of experimental results for the redistribution phase from 
Ibutop on ASC to the respective time points in the mathematical fit 
 
Fig. 4.36: Comparison of experimental results from Ibutop + DMSO on ASC to the 
respective time points in the mathematical fit 
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For the remainder of the experiments with the various types of skin using Ibutop and 
Ibutop + DMSO as formulation only one diagram per data set with relevant time 
points is presented in the following, starting with figure 4.36 for Ibutop + DMSO on 
ASC. As previously the curves of the mathematical fit are displayed in dotted lines. 
Again the content of ring #1 is slightly overestimated in the beginning and the 
opposite for later time points, yet within the error bar range. 
Figures 4.37 and 4.38 contain the diagrams from the experiments with planed human 
skin. For this skin type no early accumulation phase data is available but a close 
match to the existing results was possible. The assumptions of the model for rings 
#1 - #3 are acceptable but for rings #4 and #5 higher contents were expected as 
shown in figure 4.37. 
Using Ibutop + DMSO also the 180 and 300 minutes curves in figure 4.38 are 
matched sufficiently. For ring segments #1 - #3 in the 330 minutes diagram the fitted 
curve also ranges within the error bars but does not show the same extent of 
shoulder as assumed from the experimental data. The most distal rings (#4 and #5) 
were expected to contain more ibuprofen at later times.  
The approximation to the experimental curves obtained from the full thickness human 
skin experiments as displayed in figures 4.39 and 4.40 shows good results for most 
curves. Yet the segment #3 from Ibutop on FHS (figure 4.39) is systematically 
calculated higher than the found results from praxis.  
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Fig. 4.37: Comparison of experimental results from Ibutop on PHS to the respective 
time points in the mathematical fit 
 
Fig. 4.38: Comparison of experimental results from Ibutop + DMSO on PHS to the 
respective time points in the mathematical fit 
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Fig. 4.39: Comparison of experimental results from Ibutop on FHS to the respective 
time points in the mathematical fit 
 
Fig. 4.40: Comparison of experimental results from Ibutop + DMSO on FHS to the 
respective time points in the mathematical fit 
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Regarding the curves obtained with Ibutop + DMSO on FHS (fig. 4.40) especially the 
deviation from the sigmoidal shape for the 390 minutes attracts attention. Although 
most of the practically determined ring segment contents are in good agreement with 
the fitted graph, ring segment #2 contained relevantly greater amounts of ibuprofen 
than were calculated. Even for later simulated time points this level would not be 
reached using the same parameters matching the curves from the other time points. 
The parameters used for the best fit of the functional values from equation 4.1 to the 
respective experimental data set are given in the following table. 
Table 4.3: Values for the several parameters used to fit to experimental 
results 
ASC PHS FHS  
Ibutop Ibutop + 
DMSO 
Ibutop Ibutop + 
DMSO 
Ibutop Ibutop + 
DMSO 
Cmax [µg/mm²] 0.51 0.52 0.48 0.5 0.85 0.95
tmax [min] 100 95 200 200 240 260
a 12000 15000 20000 25000 15000 25000
b 1.026 1.030 1.035 1.034 1.026 1.028
s 2.6 2.5 2.8 2.8 2.7 2.7
r 15 15 15 15 13 15
 
Comparing the parameters listed in table 4.3 across the different skin types and 
formulations especially two parameters stand out due to a systematic difference 
between formulations on the same type of skin. Firstly the Cmax value always was 
slightly higher using the DMSO containing formulation which supports the findings 
and interpretation from 4.2.4 that DMSO slightly improves the solubility of ibuprofen 
in the skin and secondly for the parameter a, influencing mainly the accumulation 
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phase, greater values had to be chosen so a connection with skin permeability is 
assumed. 
For tmax no systematic trend within one type of skin is detectable. Using the chosen 
values for the evaluation of the missing shoulder for ASC (see 4.2.4, table 4.1) leads 
to the same conclusion. 
The remaining parameters only show slight skin type related differences (b and s) or 
appear to be almost constant (r). 
Overall the model allows to fit content profiles over time and distance with sufficient 
congruence to the experimental data set and to deduct some comparative 
parameters for each set. 
4.4 Permeation experiments 
The permeation experiments (3.2.8) characterize mainly the barrier function of the 
different types of skin by the determination of the respective ibuprofen flux and 
permeation coefficient in dependence of the donor formulation. From these results a 
quantitative comparison of the barrier function (2.2) as well as the efficacy of the 
permeation enhancers (2.2.2.3) can be estimated.  
4.4.1 Determination of flux and permeation coefficient 
While numerous permeation studies also with ibuprofen are available from literature 
[Hadgraft et al., 2003; Gonzales and Sumano, 2007] the aim for these experiments is 
to generate supportive data for the interpretation of the results from the lateral 
diffusion experiments. The experimental set up as described in 3.2.8 was therefore 
chosen in order to be identical to the diffusion experiments and thus to deviate from 
the classic modified Franz diffusion cell set up by intention. From the experimental 
results the cumulated amount of permeated ibuprofen per skin surface in contact with 
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the donor [µg/cm²] is calculated and plotted over permeation time [min]. The linear 
slope of the resulting diagram allows a calculation of the effective drug flux (2.3.1, 
equation 2.3) leading to the permeation coefficient (2.3.1, equation 2.4) taking the 
drug concentration in the formulation into account. 
4.4.1.1 Full thickness human skin 
FHS (3.2.5) is not suitable for permeation experiments due to the thickness of the 
material. During a for the diffusion experiments relevant period of eight hours no 
detectable amount of ibuprofen was found in the buffer medium. It must be 
concluded that penetration takes place but all active substance remains within the 
skin sample. This result is in good agreement with Hadgraft et al. [2003]. 
4.4.1.2 Planed human skin 
Reducing the thickness of the skin by removing large parts of the hydrophilic viable 
tissue leads to an analytically accessible permeation through the native skin (3.2.6). 
The lag-time of the experiments lies within a normal range of about 30 minutes for all 
formulations and a sufficient relative standard deviation for n = 6 experiments is 
obtained. 
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Fig. 4.41: Permeation of ibuprofen acid from Ibutop, Ibutop + Urea and Ibutop + 
DMSO through planed human skin 
The diagram 4.41 gives a comparative overview on the ibuprofen permeation through 
PHS from the three formulations plotting the permeated drug amount [µg/cm²] over 
time [min]. 
It can clearly be observed that both enhancers improve the drug permeation to a 
significant degree. DMSO is obviously more effective in reducing the diffusion barrier 
compared to urea.  
From the slope of a linear fit to each graph the flux and permeation coefficient was 
calculated and the respective results are presented in the table 4.4. 
The results for permeation from Ibutop are reasonably close to previously published 
results for ibuprofen permeation from Ibutop on fully hydrated excised human stratum 
corneum showing a flux (J) of 1.85⋅10-9 [g/cm²⋅s] [Stoye, 1997] and a permeation 
coefficient (P) of 3.70⋅10-8 [cm/s] [Specht et al., 1998 a]. 
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Table 4.4: Ibuprofen flux and permeation coefficient for PHS 
Formulation  Flux  
J [g/cm²⋅s] 
Permeation coefficient  
P [cm/s] 
Ibutop  
[n=6] 
1.32⋅10-9 
± 0.11⋅10-9
2.63⋅10-8 
± 0.22⋅10-8
Ibutop + 5% urea 
[n=6] 
1.87⋅10-9 
± 0.14⋅10-9
3.75⋅10-8 
± 0.22⋅10-8
Ibutop + 5% DMSO 
[n=6] 
2.32⋅10-9 
± 0.16⋅10-9
4.65⋅10-8 
± 0.32⋅10-8
 
4.4.1.3 Artificial skin construct 
Since the quality of the barrier function of the ASC (3.2.4) might differ in between 
batches some permeation experiments were carried out several times using different 
ASC batches to provide information of the reproducibility of the barrier function. In 
such cases the individual results are displayed in the table accompanied by an 
average result in the table in bold print. 
The average values are in good agreement with the results reported by 
Specht [1998 b] of J=3.81⋅10-8 ± 0.55⋅10-8 [g/cm²⋅s] and P=7.62⋅10-7 ± 1.1⋅10-7 [cm/s] 
[Specht et al., 1998 a] also produced with Ibutop on ASC using a similar 
experimental set up, yet with a slightly bigger donor contact area. Using a modified 
Franz cell Winkler [2005] obtained an average permeation coefficient of P=8.70⋅10-7 ± 
0.92⋅10-7 [cm/s] for the permeation of ibuprofen from Ibutop through ASC.  
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Table 4.5: Ibuprofen flux and permeation coefficient for ASC from Ibutop 
Formulation  Flux  
J [g/cm²⋅s] 
Permeation coefficient  
P [cm/s] 
Ibutop 
[n=6] 
3.07⋅10-8 
± 0.47⋅10-8
6.14⋅10-7 
± 0.94⋅10-7
Ibutop  
[n=6] 
4.81⋅10-8 
± 0.87⋅10-8
9.61⋅10-7 
± 1.75⋅10-7
Ibutop  
[n=5] 
3.86⋅10-8 
± 0.39⋅10-8
7.71⋅10-7 
± 0.77⋅10-7
Average  
[n=17] 
3.91⋅10-8 
± 0.95⋅10-8
7.83⋅10-7 
± 1.89⋅10-7
 
Also the permeation from Ibutop + DMSO was carried out in duplicate which 
produced the results given in table 4.6. 
For the visual comparison in figure 4.42 only one representative graph deriving from 
one set of experimental results per formulation is shown since an averaging of the 
individual sets of cumulated drug amounts versus time is not feasible. 
Again clearly DMSO increases the permeated amount of ibuprofen to a greater 
extent than urea. This is also expressed by the results from the following table 4.7. 
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Table 4.6: Ibuprofen flux and permeation coefficient for ASC from Ibutop + 
5% DMSO 
Formulation  Flux  
J [g/cm²⋅s] 
Permeation coefficient  
P [cm/s] 
Ibutop + 5% DMSO
[n=6] 
5.79⋅10-8 
± 0.66⋅10-8
1.16⋅10-6 
± 0.13⋅10-6
Ibutop + 5% DMSO
[n=6] 
7.45⋅10-8 
± 0.76⋅10-8
1.49⋅10-6 
± 0.15⋅10-6
Average 
[n=12] 
6.62⋅10-8 
± 1.10⋅10-8
1.32⋅10-6 
± 0.22⋅10-6
 
 
Fig. 4.42: Permeation of ibuprofen acid from Ibutop, Ibutop + Urea and Ibutop + 
DMSO through the artificial skin construct 
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Table 4.7: Ibuprofen flux and permeation coefficient for ASC 
Formulation  Flux  
J [g/cm²⋅s] 
Permeation coefficient  
P [cm/s] 
Ibutop  
[n=17] 
3.91⋅10-8 
± 0.95⋅10-8
7.83⋅10-7 
± 1.89⋅10-7
Ibutop + 5% urea 
[n=6] 
5.59⋅10-8 
± 0.28⋅10-8
1.12⋅10-6 
± 0.⋅06-6
Ibutop + 5% DMSO 
[n=12] 
6.62⋅10-8 
± 1.10⋅10-8
1.32⋅10-6 
± 0.22⋅10-6
 
4.4.2 Comparison of the barrier function 
The comparison of PHS to ASC using the calculated fluxes for the respective 
formulations allows an evaluation of the transferability of results obtained with one 
skin type towards the other. Therefore the ratio of the flux obtained from ASC to PHS 
is calculated and presented in the following table 4.8. 
Table 4.8: Ratio of the flux J from ASC/PHS for the three formulations 
Flux J [g/cm²⋅s] ASC PHS Ratio J ASC / J PHS
Ibutop 3.91⋅10-8 1.32⋅10-9 29.7 
Ibutop + 5% urea 5.59⋅10-8 1.87⋅10-9 29.8 
Ibutop + 5% DMSO 6.62⋅10-8 2.32⋅10-9 28.5 
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For all three formulations an about thirty fold higher barrier function for the native skin 
PHS is detected in comparison to the diffusion barrier of ASC. The influence of the 
permeation enhancers urea and DMSO respectively is seen to an equal extent for 
both skin types. 
4.4.3 Relative permeation enhancement 
Taking the flux J [g/cm²⋅s] obtained from the permeation of Ibutop for each skin type 
individually as reference value, the relative permeation enhancement by the addition 
of 5% urea or DMSO can be calculated. 
It can clearly be seen from the results given in table 4.9 that for both skin types a 
permeation enhancement by the factor of about 1.4 for the addition of 5 % urea and 
about 1.7 for the addition of 5 % DMSO is registered. 
Table 4.9:  Relative permeation enhancement by urea or DMSO for ASC and 
PHS 
 ASC PHS 
Ibutop 1.00 1.00 
Ibutop + 5% urea 1.43 1.43 
Ibutop + 5% DMSO 1.69 1.77 
 
The finding that DMSO is the more effective permeation enhancer compared to urea 
was expected since DMSO is known to act on multiple sites [Barry, 1991] (see 
2.5.2.1) creating synergistic effects as previously described in 2.2.2 and 2.2.2.3 while 
the mode of action for urea is the keratolytic effect reducing the keratinocyte and 
corneocyte coherence (see 2.5.2.2). 
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4.5 Total drug amount from diffusion and permeation experiments 
Due to the finding, that decisive differences in drug concentrations within the first two 
ring segments (#1 and #2) were seen between FHS and PHS (see 4.2.4) although 
both are native human tissues and similar barrier properties are to be assumed, the 
total absolute amount of penetrated / permeated ibuprofen over time was calculated 
from the previous data. For this the determined drug amounts per ring segment at a 
certain time point were summed for each type of skin in order to give the total amount 
of drug substance in the skin. Additionally the total permeated ibuprofen amount for 
each diffusion time point was calculated using the in 4.4.1.2 and 4.4.1.3 determined 
flux (J) for each skin and formulation combination, respectively (see annex 8.2).  
4.5.1 Comparison of FHS to PHS 
The effect of the previous finding of greater drug amounts in ring #1 and #2 for FHS 
can be comprehended from figure 4.43 showing the increase of total drug amount in 
the skin sample over time for FHS and PHS. 
While the overlapping error bars indicate no relevant difference for the diffusion 
experiments using Ibutop only as donor formulation, for the comparison of both skin 
types using Ibutop + DMSO significantly different drug amounts are seen throughout 
the complete time scale (ρ < 0.001 at 180 min; ρ < 0.001 at 330 min). Furthermore it 
can be clearly seen that for FHS using Ibutop a constant drug level after 270 minutes 
is reached in contrast to the DMSO containing formulation with steadily increasing 
drug amounts leading to significantly greater total drug amounts (ρ < 0.001 at 
330 min). This could be explained by decreasing sink conditions within the FHS over 
time using Ibutop in contrast to the effect of improved solubility of ibuprofen due to 
DMSO especially in the hydrophilic viable parts of the epidermis and dermis. 
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Fig. 4.43: Development of total ibuprofen amount within the complete skin samples 
of FHS and PHS depending on the respective formulation 
Adding the total permeated drug amount at each time point to the amount contained 
in the skin itself for PHS a direct comparability to the results from FHS showing no 
drug permeation is reached. This summation shifts the curves for PHS towards 
greater drug amounts as can be seen in figure 4.44 and indicates greater equality of 
the results obtained from FHS and PHS. The differences between the respective skin 
curves belonging to one formulation type are not significant anymore and can be 
explained by tissue donor differences. 
It can also be seen that the distance between the PHS curves for the two 
formulations increases by addition of the permeation values due to DMSO’s 
permeation enhancing effects. This on the other hand indicates that the difference 
between the PHS curves in figure 4.43 is mainly connected to the enhancer action on 
lateral diffusion and improved solubility of ibuprofen in the skin. 
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Fig. 4.44: Development of total ibuprofen amount in the acceptor medium and the 
complete skin samples depending on the respective formulation 
4.5.2 Comparison of ASC to PHS 
As was already noted in 4.2.4 quite similar drug levels were determined during the 
two phases of diffusion development using both formulations on ASC and PHS, 
respectively. So it is not surprising that the total drug amount in the complete skin 
samples (sum of ring #1 to #5) also develop similarly, yet with different timing. For 
the display in figure 4.45 the curves for PHS results were shifted by -120 minutes 
(which is roughly the time difference between the modeled tmax values from table 4.3) 
and then closely match the curves obtained from ASC. 
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Fig. 4.45: Development of total ibuprofen amount within the complete skin sample 
depending on the respective formulation (PHS on secondary axes of 
coordinates in red) 
Although no significant difference can be shown, overall a good tendency for higher 
ibuprofen content in the skin samples is achieved using the DMSO containing 
formulation with both, ASC and PHS. This congruence demonstrates the similarity of 
enhancer effects on the lateral diffusion for the two types of skin. 
While the summation of the permeated drug amount to the skin content leads to 
better comparability between FHS and PHS this clearly is not the case for ASC and 
PHS as can be seen in figure 4.46. Due to the lower permeation barrier properties of 
the ASC a different magnitude of permeated drug amounts separates the curves of 
two types of skin. 
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Fig. 4.46: Development of total ibuprofen amount in the acceptor medium and the 
complete skin samples depending on the respective formulation (PHS on 
secondary axes of coordinates in red) 
Most interestingly the development of drug amounts in the skin is apparently not 
directly connected to the permeation characteristics of the skin type. Although the 
amount of drug substance permeating in vertical direction per time unit is largely 
different for the two skin types no relevant difference regarding the total amount of 
drug substance in the total skin compartment is observed. This is already 
comprehendible from the similar maximal drug concentrations in ring #1 for both PHS 
and ASC effective as driving force for the lateral diffusion process. It can therefore be 
concluded that the increase in the drug content of the skin is solely depending on the 
lateral diffusion of the active substance in combination with its solubility in the skin. 
Based on this it can be shown that all three types of skin demonstrate that DMSO not 
only enhances the drug permeation but, moreover, also the lateral diffusion leading 
to greater ibuprofen content in the skin and thus enhances forming of a drug depot. 
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The comparison of the drug contents in the skin indicates that ASC is well capable to 
produce directly comparable results to human derived skin, also with good 
differentiation between formulation effects, despite its lower permeation barrier. 
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5 Conclusion 
The effects of lateral diffusion on drug depot building within skin after dermal 
application with focus on spatiotemporal development were studied. 
The characteristics of this process taking place in an artificial skin construct in 
comparison to two types of human skin (full thickness and planed) using the active 
substance ibuprofen from different formulations were investigated.  
As far as possible also permeation experiments were carried out in order to further 
characterize the barrier properties of the different types of skin and to allow a better 
interpretation of differences seen in the diffusion experiments. 
5.1 Lateral diffusion process 
5.1.1 Process mechanism 
The results produced using the artificial skin construct (ASC) principally show the 
same time dependent drug concentration per distance gradient development as also 
seen with the full thickness human skin (FHS) and the planed human skin (PHS).  
This over all development is characterized by two phases. The first phase 
(accumulation) is dominated by a drug concentration increase mainly in the central 
skin area either with direct formulation contact or in direct vicinity to the formulation 
application area. Then a maximal concentration in the central area is observed and 
the second phase (redistribution) starts, which is characterized by decreasing central 
drug concentration in contrast to an increase in concentration in the distal skin area. 
Based on the determination of similar drug amounts within the ASC and the PHS in 
spite of the large difference in permeability of the skin types, it must be concluded 
that the main driving force for the lateral diffusion within the skin is not the 
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permeation coefficient but more likely the resulting concentration of drug in the skin 
at the site of formulation application. This concentration is certainly depending on the 
permeation coefficient as velocity parameter but moreover on the total solubility of 
the drug substance in the skin. 
The observation of a concentration maximum in the central segment indicates that 
the lateral diffusion of ibuprofen starts with a certain time lag. Before the lateral 
diffusion is fully established the drug substance accumulates in the skin and is only 
reduced by effective permeation into the acceptor medium. Thus, a sole vertical 
transport route (one dimensional) is predominant in that phase. When the lateral 
diffusion becomes relevant after the lag time two additional directions in the plane of 
the skin surface are available for drug wash-out from the central segment. This then 
three dimensional drainage causes the decrease in central drug content until steady 
state equilibrium is reached with the rate limiting step for drug influx of either 
penetration into the stratum corneum or even release from the formulation. The latter 
is assumed to be the case for diffusion using ASC since the results from the 
permeation experiments with ASC show a slight bend towards smaller slope in the 
permeation diagrams at about 100 - 120 minutes especially noticeable for the 
additional enhancer containing formulations. The timing of this bend coincides with 
the estimated time for maximal drug concentration in ASC from the fitted 
mathematical model. Hence the bend is a direct result from the additional competitive 
lateral diffusion. This bend in permeation curves was also observed by 
Specht [1998 b] at the same time point using a similar methodological set up for 
permeation experiments with a slightly larger application surface but still with 
sufficient surrounding skin to allow for lateral diffusion. 
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The lag time for effective lateral diffusion should depend largely on the co-diffusion of 
solubility increasing excipients like in this case propylene glycol from the Ibutop 
formulation. This assumption is in good agreement with the finding of Nicoli et al. 
[2009] demonstrating that clearance of ibuprofen from the stratum corneum is 
significantly reduced if the propylene glycol containing formulation is removed from 
the skin and the treated area is left unoccluded so that the volatile propylene glycol 
can evaporate from the skin. 
The results from penetration studies with ibuprofen presenting depth profiles 
obtained by tape stripping show, that the drug concentration declines exponentially 
within the 15 - 20 µm distance of the stratum corneum [Bock et al., 2004; Nicoli et al., 
2009]. A similar exponential decline is seen with the results of this work but over a 
lateral distance of several millimeters. This emphasizes the proposal of Johnson et 
al. [1997] that the lateral diffusion in the stratum corneum lipid bilayers is the main 
transport mechanism for lipophilic drugs. The findings of Ashworth et al. [1988] that 
higher concentrations of clobetasol 17-propinate in upper stratum corneum layers 
correlate with larger lateral drug transport compared to a second formulation showing 
the greater drug amounts in lower stratum corneum layers with less lateral diffusion 
indicate that this phenomenon is depending on the formulation. 
5.1.2 Relevance 
While in typical studies the occurrence of lateral diffusion is considered as a possible 
cause of error [Dreher et al., 2002; Weigmann et al., 1999] for inaccurate penetration 
rates during this investigation it was intently included. The results from this study 
show that the lateral drug diffusion must not be disregarded for in vitro experiments 
using significantly larger skin sample sizes than required for donor contact area. 
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The relevance of lateral diffusion for in vivo experiments is even greater. In 
therapeutic use the topical application of a drug loaded vehicle normally takes place 
by localized administration. So there will always be untreated adjacent sites 
functioning as possible compartments for laterally diffused substances. This has 
been impressively demonstrated by Simonsen et al. [2002] and Weigmann et al. 
[1999]. Furthermore the comparison of the permeated drug amounts to the amounts 
found in the skin using PHS in this work underlines that during treatment times of up 
to five hours 4 – 5 fold larger drug amounts accumulate in the skin, building a depot 
with a large quantity of drug contained in lateral skin areas. 
The relevance of the lateral diffusion process on the dermal absorption depending on 
the spatial distribution has been described mathematically by Reddy and Bunge 
[2000] emphasizing that when the area fraction of the exposed skin in contact with 
the chemical is held constant, dermal absorption is larger from many small piles 
without being in close contact to each other than from a few large piles close 
together.  
This interrelation has been demonstrated by Karande and Mitragotri [2003] 
investigating the relative permeation increase of model drug when multiple small 
circular compartments were used instead of one big circular compartment of the 
same total surface area. But the results have not been explained by the effects of 
lateral diffusion but by a lateral strain in the skin due to preferential swelling of the 
skin. This is in contrast to the findings from Lévêque et al. [2002 b] indicating that 
skin deformation does not have a significant impact on permeability. 
Yet the experimentally determined results from Karande can easily be explained by 
the influence of lateral diffusion. The fragmentation of the one big reference area into 
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multiple smaller areas practically enlarges the available surface of tissue for lateral 
diffusion over the same distance w as can be seen in figure 5.1. 
w 
w w w 
 
Fig. 5.1: Visualization of the relative increase of surface for lateral diffusion by 
fragmentation of the donor area 
This relative lateral surface increase (matching the normalized permeation 
enhancement PE(r) used by Karande) can be calculated using equation 5.1 which 
expresses the surface ratio of n lateral rings of width w around the small donors with 
radius r to one lateral ring of width w around one large donor with radius rref. 
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The virtual width of the lateral ring should be an indirect parameter for effectiveness 
of lateral diffusion and thus be specific for a certain drug formulation. 
The comparison of the experimental results from Karande to the mathematical fit 
using equation 5.2 (with w = 6 mm) is given in figure 5.2 displaying the normalized 
permeation enhancement over the inverse radius of the several application 
reservoirs. 
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Fig. 5.2: Comparison of the experimentally determined dependence of skin 
permeability (relative to that of a 6 mm reservoir) to the modeled 
enhancement on the basis of relative lateral surface increase 
This observation indicates special relevance for systemically administered drugs, for 
instance from a transdermal therapeutic system of the matrix type. These matrix 
patches are often cut to a specific area for dose adaptation. If the dissected patch 
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fragment is kept and later applied together with other fragments giving the same total 
area a significantly greater total dose may be applied. 
A study about ketoprofen permeation / penetration conducted by Bock et al. [2004] 
showed a maximal concentration in the in vivo experiments at the treated site after 
3 h while the 6 h results were noticeably lower. The authors attribute this observation 
(similar to the observed maxima in this work) to the effects of skin hydration after the 
6 h occlusion on the tape stripping leading to non-uniform strips and excluded the 
results from further evaluation. Yet this finding could principally also be explained by 
lateral diffusion reducing the drug concentration as shown in this work. Since the 
adjacent sites were not included in the tape stripping this cannot be finally evaluated. 
5.2 Comparison of the artificial skin construct to human skin types 
5.2.1 Lateral diffusion 
Good comparability using ASC can be shown to PHS while the influence on skin’s 
drug content by permeation into the acceptor medium is neglected using the FHS 
leading to greater contained amounts.  
The two phase (accumulation / redistribution) process develops more quickly in ASC 
compared to the two human skin types. So the occurrence of the maximum 
concentration in the central area is observed in less than half of the duration. This 
difference is attributed to the lower permeation barrier of the ASC compared to 
human stratum corneum as is known from Specht et al. [1998 a] and Winkler and 
Müller-Goymann [2002] making a quicker invasion of ibuprofen reasonable. 
Another difference between ASC and the human skins is seen during the 
redistribution phase. Typically the concentration gradient curve in the human skins 
develops from an exponentially shaped decrease over rings one to three to a shape 
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forming a shoulder due to concentration decrease in ring one while rings two and 
three maintain their concentration or even increase, respectively. This development 
is not observed to the same extent in ASC. Here the decline in the central ring 
segment is relatively smaller so that the exponential shape is maintained and at the 
same time the increase in distal concentration is increased suggesting larger lateral 
diffusion. 
With regard to the larger increase in lateral drug amounts for the ASC an error 
source due to a lateral spreading of the formulation on the skin as described by 
Giese et al. [2000] of up to 20 mm in 11 min can be excluded. It is rather to be 
suspected that a reuptake of ibuprofen from the acceptor medium into the skin could 
take place which would be more pronounced for ASC compared to PHS since 
significantly greater amounts of drug permeate into the acceptor compartment. The 
more distal ring segments should be most affected due to their lower intrinsic drug 
concentration. This potential artifact could be avoided by increasing the volume of the 
acceptor medium by the ratio of permeation coefficients from ASC to PHS and 
requires further investigation. With regard to the total drug amounts contained in the 
complete skin sample, irrespective if central or lateral, this deviation is of minor 
influence. 
Over all a good analogy could be shown for the concentration development in ASC 
and PHS. Furthermore the use of the formulations Ibutop and Ibutop + 5 % DMSO on 
both ASC and PHS allow highly similar differentiation of the enhancer effect with 
regard to the total drug amounts in the several skin segments and thus the depot 
building. In a principal differentiation between the two formulations all three skin 
types show the trend to reach a plateau of drug content in the skin using Ibutop only 
while with Ibutop + 5 % DMSO a continuous increase in drug amounts over time is 
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seen. This continuous increase is explicable from the increased permeation rate in 
combination with improved drug solubility in the skin. 
Regarding the comparison to FHS no direct comparability of drug amounts per 
segment is seen due to the distortion of the results by lack of drug permeation in 
FHS. Yet in the relative, percental comparison of laterally diffused drug amounts 
good comparison for all three skin types is shown. 
5.2.2 Permeation results 
Although Specht et al. [1998 a] have already shown that the ASC differentiates 
between permeation rates from formulations comparably to stratum corneum, the 
permeation from Ibutop and the two additional enhancer (urea / DMSO) containing 
variations was investigated using the set up from the diffusion experiments. These 
results should provide comparability to PHS and give insight into the influence of the 
permeation coefficient on the lateral diffusion. The high similarity of relative 
permeation enhancement between ASC and PHS in combination with the similarity of 
the lateral diffusion results provides a good predictability of depot effects from ASC 
results despite the roughly 30-fold lower diffusion barrier for all three formulations. 
5.2.3 Diffusion model fitting 
Based on the obtained results from the diffusion experiments a mathematical function 
was developed empirically allowing to match the observed results from multiple 
experiments belonging to one result set for lateral diffusion using the parameters 
Cmax and tmax.  
Although the function has a general tendency to overestimate early and 
underestimate late ring #1 drug concentration the model is able to describe the 
concentration gradient development within the standard deviation as seen from the 
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experimental results over time and distance within the timeframe of the experiments. 
The deviation in early and late estimation is deriving from the term describing the 
accumulation phase which produces a bell shaped curve returning to almost zero for 
large diffusion times which should be incorrect for late diffusion times but steady 
state equilibrium significantly greater than zero should be reached. The parameter a 
largely controls the shape of this term and therefore the speed of concentration 
increase and decrease in the central ring segment. Interestingly the parameter ratio 
(Ibutop / Ibutop + DMSO) for this factor a from the parametrical fit is exactly identical 
for ASC and PHS. This and the only minimal variability of the other remaining 
parameters indicate the high similarity of the lateral diffusion or depot building 
process between ASC and the human skin in vitro. 
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6 Summary 
The aim of this study is to investigate the spatial drug concentration development 
within skin focusing especially on effects of lateral drug diffusion and the 
accompanying drug depot formation. Furthermore a comparison of the effects seen 
within an artificial skin construct (ASC) to the development in human skin is carried 
out in order to evaluate the suitability of the ASC for more complex diffusion studies. 
For this an experimental set up especially provoking a larger influence of lateral 
diffusion was developed. Diffusion experiments with ASC, planed human skin (PHS) 
and full thickness human skin (FHS) were carried out using the ibuprofen containing 
commercial formulation Ibutop Creme, Ibutop + 5 % urea and Ibutop + 5 % DMSO for 
several time points. The drug concentration profile was then determined by 
dissecting the skin sample into five concentric rings which were analyzed separately 
on their ibuprofen content. 
It was shown that the spatial concentration development in all skin types follows the 
same principal pattern characterized by an initial increase in the central skin section 
which is in direct contact with the formulation and only slight lateral diffusion into the 
two directly adjacent skin segments so that larger drug amounts accumulate in the 
central area. Then the effect of lateral diffusion increases and the drug concentration 
in the central segment decreases while the lateral diffusion leads to a continuous 
increase in the lateral skin segments by redistribution. The observed concentration 
maximum for the central skin segment is explained by the lag time for the effective 
lateral diffusion leading then to a three dimensional drainage compared to the mainly 
vertical (one dimensional) diffusion during the accumulation phase. 
From these observations a relevant depot building in the skin areas adjacent to the 
site of application can be proven. The comparison of the total drug amount in the 
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complete skin sample (sum of rings #1 to #5 of PHS) in relation to the amount 
permeated through PHS during the time frame of the experiments reveals the 
relevance of this depot building since 4 – 5 times greater amounts of drug than found 
in the acceptor medium were determined in the skin with a large fraction in the lateral 
skin segments. 
The use of the additional permeation enhancers mainly lead to larger amounts in the 
skin but not to a relatively greater lateral diffusion. 
The comparison of the results obtained with ASC to those from PHS and FHS show 
some skin type dependent differences. So the time frame for the concentration profile 
development as observed in the human skins is largely reduced in ASC which is 
attributed to the lower permeation barrier. On the other hand the results obtained with 
FHS show significantly larger amounts of ibuprofen in the skin. This can be explained 
by the lack of drug permeation using this skin so that also the amounts otherwise 
found in the acceptor were retained in the skin. Hence a direct comparison of ASC to 
FHS is not feasible but the comparison to PHS shows that very close resemblance 
between these two skin types is obtained. This is true for the individual skin segment 
concentration as well as for the total amount in the skin with a similar differentiation 
between enhancer containing formulation to Ibutop alone. This high similarity might 
mainly be based on the very good comparability of the relative permeation enhancing 
effect of the respective formulations that could be shown in the permeation 
experiments. 
A parametric fit of an empirically developed function to the diffusion results supports 
that the mechanisms within ASC and human skin responsible for lateral diffusion and 
thus depot building are highly similar and the use of ASC for studies on drug diffusion 
in and through skin is reasonable. 
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8 Annex 
The data in this annex provides the basis for the diagrams which were presented in 
the results and discussion section (4.2 and 4.5) and are included for consultation in 
case a more detailed comparison of results than possible from the graphs is needed.  
8.1 Data from diffusion experiments 
8.1.1 Full thickness human skin (FHS) 
8.1.1.1 Ibutop on FHS 
Table 8.1: Ibuprofen content of the ring segments in [µg/mm2] for the 
respective diffusion experiment time periods using Ibutop on FHS 
Ibutop  
on FHS 
Ring #1  
[1.25 mm] 
Ring #2  
[3.75 mm] 
Ring #3  
[6.25 mm] 
Ring #4  
[8.75 mm] 
Ring #5  
[11.0 mm] 
Duration n= Ø ± SD Ø ± SD Ø ± SD Ø ± SD Ø ± SD 
90 min 4 0.283 ±0.040 0.157 ±0.040 0.021 ±0.002 0.005 ±0.007 0.000 ±0.000
195 min 5 0.554 ±0.065 0.244 ±0.065 0.027 ±0.030 0.011 ±0.003 0.000 ±0.000
270 min 5 0.771 ±0.179 0.249 ±0.026 0.007 ±0.016 0.007 ±0.010 0.018 ±0.011
330 min 5 0.470 ±0.091 0.231 ±0.031 0.031 ±0.007 0.015 ±0.014 0.021 ±0.009
390 min 6 0.355 ±0.068 0.275 ±0.036 0.060 ±0.007 0.020 ±0.011 0.018 ±0.008
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8.1.1.2 Ibutop + 5 % urea on FHS 
Table 8.2: Ibuprofen content of the ring segments in [µg/mm2] for the 
respective diffusion experiment time periods using Ibutop + 5 % 
urea on FHS 
Ibutop+urea 
on FHS 
Ring #1  
[1.25 mm] 
Ring #2  
[3.75 mm] 
Ring #3  
[6.25 mm] 
Ring #4  
[8.75 mm] 
Ring #5  
[11.0 mm] 
Duration n= Ø ± SD Ø ± SD Ø ± SD Ø ± SD Ø ± SD 
90 min 6 0.322 ±0.034 0.159 ±0.029 0.030 ±0.005 0.008 ±0.003 0.009 ±0.003
180 min 6 0.624 ±0.080 0.265 ±0.042 0.040 ±0.007 0.014 ±0.003 0.011 ±0.004
270 min 6 0.803 ±0.126 0.269 ±0.039 0.054 ±0.011 0.026 ±0.006 0.018 ±0.006
300 min 6 0.781 ±0.098 0.315 ±0.036 0.074 ±0.010 0.033 ±0.007 0.025 ±0.006
330 min 6 0.495 ±0.058 0.330 ±0.031 0.080 ±0.010 0.038 ±0.008 0.029 ±0.006
390 min 6 0.483 ±0.068 0.370 ±0.037 0.105 ±0.015 0.046 ±0.008 0.034 ±0.006
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8.1.1.3 Ibutop + 5 % DMSO on FHS 
Table 8.3: Ibuprofen content of the ring segments in [µg/mm2] for the 
respective diffusion experiment time periods using Ibutop + 5 % 
DMSO on FHS 
Ibutop+DMSO 
on FHS 
Ring #1  
[1.25 mm] 
Ring #2  
[3.75 mm] 
Ring #3  
[6.25 mm] 
Ring #4  
[8.75 mm] 
Ring #5  
[11.0 mm] 
Duration n= Ø ± SD Ø ± SD Ø ± SD Ø ± SD Ø ± SD
90 min 6 0.324 ±0.026 0.162 ±0.024 0.031 ±0.004 0.010 ±0.003 0.009 ±0.002
180 min 6 0.640 ±0.086 0.279 ±0.026 0.044 ±0.005 0.017 ±0.003 0.013 ±0.004
270 min 6 0.805 ±0.119 0.276 ±0.024 0.055 ±0.009 0.029 ±0.003 0.021 ±0.004
300 min 6 0.747 ±0.067 0.320 ±0.037 0.080 ±0.011 0.036 ±0.005 0.026 ±0.006
330 min 6 0.609 ±0.061 0.349 ±0.037 0.101 ±0.009 0.041 ±0.009 0.032 ±0.006
390 min 6 0.556 ±0.041 0.424 ±0.038 0.126 ±0.019 0.055 ±0.010 0.039 ±0.006
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8.1.2 Planed human skin (PHS) 
8.1.2.1 Ibutop on PHS 
Table 8.4: Ibuprofen content of the ring segments in [µg/mm2] for the 
respective diffusion experiment time periods using Ibutop on PHS 
Ibutop  
on PHS 
Ring #1  
[1.25 mm] 
Ring #2  
[3.75 mm] 
Ring #3  
[6.25 mm] 
Ring #4  
[8.75 mm] 
Ring #5  
[11.0 mm] 
Duration n= Ø ± SD Ø ± SD Ø ± SD Ø ± SD Ø ± SD 
180 min 6 0.405 ±0.052 0.128 ±0.026 0.044 ±0.019 0.011 ±0.004 0.000 ±0.000
240 min 6 0.443 ±0.044 0.151 ±0.025 0.057 ±0.016 0.014 ±0.004 0.001 ±0.001
300 min 6 0.288 ±0.033 0.182 ±0.024 0.069 ±0.013 0.019 ±0.007 0.003 ±0.002
330 min 6 0.231 ±0.034 0.181 ±0.037 0.092 ±0.017 0.023 ±0.008 0.008 ±0.005
 
8.1.2.2 Ibutop + 5 % DMSO on PHS 
Table 8.5: Ibuprofen content of the ring segments in [µg/mm2] for the 
respective diffusion experiment time periods using Ibutop + 5 % 
DMSO on PHS 
Ibutop+DMSO 
on PHS 
Ring #1  
[1.25 mm] 
Ring #2  
[3.75 mm] 
Ring #3  
[6.25 mm] 
Ring #4  
[8.75 mm] 
Ring #5  
[11.0 mm] 
Duration n= Ø ± SD Ø ± SD Ø ± SD Ø ± SD Ø ± SD
180 min 6 0.415 ±0.036 0.136 ±0.019 0.049 ±0.015 0.013 ±0.004 0.000 ±0.000
240 min 6 0.459 ±0.048 0.159 ±0.017 0.072 ±0.008 0.019 ±0.005 0.005 ±0.003
300 min 6 0.314 ±0.031 0.203 ±0.021 0.085 ±0.010 0.024 ±0.006 0.009 ±0.005
330 min 6 0.263 ±0.030 0.222 ±0.018 0.112 ±0.013 0.037 ±0.008 0.013 ±0.006
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8.1.3 Artificial skin construct (ASC) 
8.1.3.1 Ibutop on ASC 
Table 8.6: Ibuprofen content of the ring segments in [µg/mm2] for the 
respective diffusion experiment time periods using Ibutop on ASC 
Ibutop  
on ASC 
Ring #1  
[1.25 mm] 
Ring #2  
[3.75 mm] 
Ring #3  
[6.25 mm] 
Ring #4  
[8.75 mm] 
Ring #5  
[11.0 mm] 
Duration n= Ø ± SD Ø ± SD Ø ± SD Ø ± SD Ø ± SD
10 min 5 0.224 ±0.050 0.117 ±0.025 0.031 ±0.008 0.016 ±0.005 0.011 ±0.008
30 min 5 0.298 ±0.031 0.126 ±0.017 0.028 ±0.006 0.009 ±0.002 0.003 ±0.004
60 min 5 0.436 ±0.069 0.137 ±0.034 0.037 ±0.013 0.012 ±0.004 0.000 ±0.000
135 min 3 0.409 ±0.005 0.139 ±0.010 0.050 ±0.007 0.030 ±0.006 0.009 ±0.004
210 min 4 0.347 ±0.057 0.106 ±0.036 0.045 ±0.006 0.049 ±0.004 0.000 ±0.000
250 min 3 0.263 ±0.012 0.127 ±0.000 0.075 ±0.017 0.054 ±0.000 0.039 ±0.007
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8.1.3.2 Ibutop + 5 % DMSO on ASC 
Table 8.7: Ibuprofen content of the ring segments in [µg/mm2] for the 
respective diffusion experiment time periods using Ibutop + 5 % 
DMSO on ASC 
Ibutop+DMSO 
on ASC 
Ring #1  
[1.25 mm] 
Ring #2  
[3.75 mm] 
Ring #3  
[6.25 mm] 
Ring #4  
[8.75 mm] 
Ring #5  
[11.0 mm] 
Duration n= Ø ± SD Ø ± SD Ø ± SD Ø ± SD Ø ± SD
10 min 6 0.243 ±0.046 0.131 ±0.022 0.039 ±0.008 0.020 ±0.008 0.010 ±0.005
30 min 6 0.314 ±0.042 0.155 ±0.022 0.045 ±0.008 0.023 ±0.007 0.005 ±0.003
60 min 6 0.466 ±0.051 0.163 ±0.023 0.041 ±0.008 0.019 ±0.006 0.013 ±0.007
120 min 6 0.440 ±0.069 0.176 ±0.018 0.052 ±0.011 0.025 ±0.008 0.018 ±0.008
180 min 6 0.376 ±0.046 0.183 ±0.022 0.078 ±0.011 0.047 ±0.012 0.024 ±0.010
240 min 6 0.311 ±0.038 0.177 ±0.016 0.086 ±0.010 0.062 ±0.015 0.042 ±0.011
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8.2 Data for total drug amount from diffusion and permeation 
experiments 
8.2.1 Ibutop on FHS, PHS and ASC 
Table 8.8: Amount of ibuprofen as sum from the ring segments’ content and 
the respective permeated amount in [µg] for the several diffusion 
experiment time periods using Ibutop on all three skin types 
 Ibutop 
Skin type Time  
[min] 
Skin content 
Ø ± SD [µg] 
Permeated amount 
Ø ± SD [µg] 
Total  
Ø ± SD [µg] 
90 17.58 ± 2.87 — 17.58 ± 2.87 
195 29.43 ± 7.18 — 29.43 ± 7.18 
270 33.87 ± 5.13 — 33.87 ± 5.13 
330 30.90 ± 2.86 — 30.90 ± 2.86 
FHS 
390 34.48 ± 4.57 — 34.48 ± 4.57 
180 21.36 ± 1.65 2.79 ± 0.23 24.15 ± 1.89 
240 25.30 ± 2.09 3.72 ± 0.31 29.02 ± 2.40 
300 26.28 ± 3.28 4.65 ± 0.39 30.93 ± 3.67 
PHS 
330 28.50 ± 4.18 5.11 ± 0.43 33.62 ± 4.61 
10 18.17 ± 3.28 4.61 ± 1.12 22.77 ± 4.40 
30 17.74 ± 1.41 13.82 ± 3.36 31.56 ± 4.77 
60 21.86 ± 2.87 27.64 ± 6.72 49.51 ± 9.59 
135 26.49 ± 1.39 62.20 ± 15.11 88.69 ± 16.50 
210 24.16 ± 1.38 96.75 ± 23.50 120.92 ± 24.89 
ASC 
250 32.77 ± 2.75 115.18 ± 27.98 147.95 ± 30.73 
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8.2.2 Ibutop + 5 % DMSO on FHS, PHS and ASC 
Table 8.9: Amount of ibuprofen as sum from the ring segments’ content in 
[µg] and the respective permeated amount in [µg] for the several 
diffusion experiment time periods using Ibutop + 5 % DMSO on all 
three skin types 
 Ibutop + 5 % DMSO 
Skin type Time  
[min] 
Skin content 
Ø ± SD [µg] 
Permeated amount 
Ø ± SD [µg] 
Total  
Ø ± SD [µg] 
90 21.60 ± 1.78 — 21.60 ± 1.78 
180 37.45 ± 3.21 — 37.45 ± 3.21 
270 44.26 ± 3.28 — 44.26 ± 3.28 
330 52.41 ± 3.34 — 52.41 ± 3.34 
FHS 
390 61.21 ± 3.05 — 61.21 ± 3.05 
180 22.67 ± 1.84 4.93 ± 0.34 27.60 ± 2.18 
240 28.74 ± 2.46 6.57 ± 0.45 35.30 ± 2.91 
300 30.91 ± 3.70 8.21 ± 0.57 39.12 ± 4.26 
PHS 
330 36.10 ± 4.50 9.03 ± 0.62 45.13 ± 5.13 
10 20.36 ± 4.03 7.80 ± 1.30 28.16 ± 5.33 
30 23.50 ± 2.13 23.40 ± 3.89 46.90 ± 6.01 
60 27.20 ± 3.29 46.79 ± 7.78 74.00 ± 11.07 
120 30.09 ± 3.65 93.59 ± 15.55 123.68 ± 19.21 
180 35.51 ± 3.67 140.38 ± 23.33 175.89 ± 26.99 
ASC 
240 39.29 ± 2.45 187.18 ± 31.10 226.47 ± 33.55 
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